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CHAPTER 1 INTRODUCTION
1.1: Nanotechnology and Magnetic Nanoparticles
Nanotechnology is an emerging field of science, which includes the study of materials
with size ranging from few nanometers to several hundred nanometers and their applications to
various fields. Nanomaterials are of great scientific interest as they are effectively a bridge
between bulk materials and atomic or molecular structures and interestingly, the properties of
materials can change as their size approaches the nanoscale. In recent years, nanoparticles have
attracted a great deal of attention due their potential applications in biomedicine [1-5]. Among
nanoparticles for such use, magnetic nanoparticles have the potential to be delivered to a specific
region in the body with an external magnetic field manipulation. This requires large
magnetization for the magnetic nanoparticles so that they respond to externally applied magnetic
field at physiological temperatures. Iron oxide nanoparticles (Fe3O4), with relatively higher
saturation magnetization values are therefore suitable for this purpose. Furthermore, low toxicity,
biocompatibility, surface functionalization capabilities combined with excellent magnetic
resonance imaging (MRI) contrast property make them ideal for use in noninvasive disease
targeting, detection, and treatment. Therefore, superparamagnetic Fe3O4 nanoparticles are
currently used as one of the most important and acceptable candidates for magnetic resonance
imaging (MRI) [6-8],targeted drug delivery [9-11], magnetic hyperthermia [12-14], and cell
separation [15,16].Nanoparticles have higher surface energy due to their smaller sizes hence tend
to form agglomerates which is not favorable for their use in clinical applications. Therefore,
these nanoparticles are often coated with a surfactant making them a stable colloidal suspension
which is called a “Ferrofluid”.
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1.2: Magnetic Hyperthermia
Over the past decade, the topic of “cancer therapy” has attracted a great deal of attention
due to the huge impact it has on human life. The principle of cancer treatment is to kill the
malignant cells with the least of damage to normal cells. Distinguishing cancer cells from normal
cells is difficult, making the existing treatments such as chemotherapy and radiation therapy less
effective and fraught with various side effects Hyperthermia or heating therapy has great
potential as a complimentary cancer treatment method. It is known that the blood flow in tumor
is lower and the reduced blood flow causes the lack of oxygen which leads to the formation of
lactic acid making the cells more acidic [17]. The acidic cells which are more sensitive to
temperature, have lower thermal resistance than normal cells and the decreased blood flow in the
tumor limit their ability to dissipate heat. As a result, cancer cells can be damaged and killed by
increasing the local temperature to the range of 42 ºC to 46 ºC with little detriment to healthy
cells. Depending on the nature of the heating source and the heated target, hyperthermia is
categorized into 3 types: local, regional, and whole body hyperthermia [18] .Whole body
hyperthermia is used only when the disease has spread throughout the body and can be achieved
using hot wax, hot air, hot water suits, or infrared radiation. Regional hyperthermia where heat is
subjected to a smaller area such as a whole tissue or organ is accomplished by utilizing
ultrasound, radio frequency (RF) fields, or microwaves. Local hyperthermia involves heating a
small area of interest such as a tumor. Different approaches for inducing hyperthermia as
discussed above are illustrated in the Figure 1.1. The effectiveness of the treatment is judged by
how much of the tumor is heated to a therapeutic level and often this is very low due to lack of
heat transfer to the tumor site.
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Figure 1.1: Methods of achieving hyperthermia for cancer treatment [19].
Various nanoparticles have been used as heat mediators in local hyperthermia technique.
The most common types of nanoparticles which have been investigated for hyperthermia therapy
are listed in Table 1.1.
The idea of utilizing magnetic nanoparticles for hyperthermia was first proposed by
Gilchrist et al. in 1950s and since then many types of nanoparticles show promising results [19].
Magnetic hyperthermia, where electromagnetic energy is converted into heat by applying an
external alternating magnetic field on magnetic nanoparticles, is of particular interest as the
nanoparticles can be guided and localized specifically at a tumor site by external magnetic field
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guidance and can also be directed to the cancer cells by tagging a targeting ligand such as
antibody or peptide, without reducing its efficiency [20,21]. For example, Fabio et al. have
reported that conjugation of folate receptors enhances the targeting for magnetic hyperthermia in
solid tumors [22].
Table 1.1: Commonly studied nanoparticles for hyperthermia
Meterial

Structure

Hyperthermia type

Au

Nanorods [23,24],

Photothermal heating
(NIR)

Nanoshells [25,26]
Carbon

Nanotubes (CNT) [27-30],
Graphene oxide sheets[31]

Quantum dots (CdTe, dSe)

Fe3O4

Photothermal heating
(NIR)

[32,33]

Photothermal heating
(Radiofrequency)

Nanosheres [34-36]
Nanocubes [37-39],

Magnetic heating

Coreshell [40,41]
Magnetite (Fe3O4) and maghemite (γ-Fe2O3) have been extensively studied and are
promising candidates due to their biocompatibility and relative ease to functionalize. Figure 1.2

illustrates an example of strategy for using magnetic nanoparticles as a potential Theranostic
(Diagnostic + Theraputic) agent. Recent studies have reported the heating efficiencies in Fe3O4/γFe2O3 core-shell structures as well [42]. Additionally, iron oxide nanoparticles doped with other
magnetic dopants such as Co, Mn and Ni [43-45] are under investigation to achieve a high heating

efficiency by tuning the magnetic anisotropy and saturation magnetization of the material.
However, among numerous complications, with a high curie temperature of Fe3O4 -850K and γFe2O3- 750 K, overheating is one of the drawbacks of utilizing these nanoparticles and as a
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solution for those complex magnetic oxides with low Curie temperature are being investigated
[46-48].

Figure 1.2: Schematic illustration of the therapeutic strategy using magnetic particles.
Functionalized magnetic nanoparticles accumulate in the tumor tissues via the drug delivery
system (DDS). Magnetic nanoparticles can be used as a tool for cancer diagnosis by magnetic
resonance imaging (MRI) or for magnetoimpedance (MI) sensor. Hyperthermia can then be
induced by AMF exposure [49].
1.3: Magnetic nanoparticles based drug delivery
Over the last two decades, magnetic nanoparticles have been increasingly exploited as
platforms for transport of drugs and genes [50,51].

In magnetic drug delivery, a drug or

therapeutic reagent is conjugated to the nanoparticle and introduced in the body, and
concentrated in the target area by means of a magnetic field gradient (using an internally
implanted permanent magnet or an externally applied field) [52]. Using a targeting ligand the
targeting specificity can be enhanced. These anti-cancer drugs carried by the nanoparticles can
then be released at the tumor site via enzymatic activity, or via changes in the physiological
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conditions such as temperature and pH. Drug release can also be magnetically triggered from the
drug-conjugated magnetic nanoparticles [52-54]. For example, Hayashi et al [55] reports a study
done on superparamagnetic iron oxide nanoparticles conjugated with folic acid (well-known as a
targeting ligand for breast cancer cells), β-Cyclodextrin (which act as drug container)and
tamoxifen (anti-cancer drug). By means of an AC magnetic field, heat is generated which
triggers drug release - a behavior that is controlled by switching the high frequency magnetic
field on and off. This is capable of performing drug delivery and hyperthermia simultaneously.
Among various other anti-cancer drugs doxorubicin is widely used as a model drug. There are
several methods that can be used to load doxorubicin into nanoparticles such as by adsorption on
the nanocarrier inorganic core [56-58], by diffusion [59,60] or entrapment [61,62] in the coating
materials and by chemical bonds [63,64] with the coating of the nanocarrier. Even though
magnetic drug delivery shows a great promise in cancer treatment avoiding the side effects of
conventional chemotherapy, the designing and fabrication of an efficient nanoparticle based drug
delivery system is still a challenge.
1.4: Surface modification of magnetic nanoparticles
Nanoparticles have larger surface to volume ratio and hence possess high surface
energies. Moreover magnetic nanoparticles which are of interest for biomedical applications such
as magnetite (Fe3O4) have hydrophobic surfaces. Therefore, these particles tend to aggregates
forming large clusters resulting in increased particle size and in addition, exhibit high chemical
activity which causes them to easily oxidize in air (especially magnetite)generally resulting in
loss of magnetism and dispersibility. Therefore, providing a proper surface coating to keep the
stability of the nanoparticles is crucial. Additionally, in order to expand the scope of biological
application of nanoparticles, some molecules/surfactants are also employed to enhance its
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biocompatibility. The stable colloidal suspensions of surfactant coated iron oxides nanoparticles
are called “Ferrofluids” which are magnetizable fluids that remain as liquids in the most intense
magnetic fields and in biological media. Stabilization of the ferrofluid can be achieved by the
presence of one or both of the two repulsive forces (see Fig. 1.3): electrostatic and steric
repulsion between the particles [51]. The steric force is difficult to predict or quantify and mostly
depend on the weight and the density of the polymer used for the coating. The electrostatic
repulsion can be understood through the knowledge of the diffusion potential and mainly
depends on the ionic strength and the pH of the solution.

Figure 1.3: (a) Particles stabilized by the electrostatic layer and (b) Particles stabilized by steric
repulsion [51].
Over the years, researchers have developed various surface modification strategies
comprised of grafting of or coating with both organic and inorganic materials. In addition to the
stabilization, these protecting shells also provide a platform for further functionalization
depending on the desired application. The coating process can be done during the nanoparticles
synthesis referred to as “in situ” coating or can be done after the nanoparticle synthesis referred
as “post-synthesis”. Organic molecules include small organic molecules, macromolecules or
polymer and biological molecules. They provide various highly reactive functional groups such
as carboxyl groups, aldehyde groups and amino groups. Moreover, organic compounds
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functionalized nanoparticles preserve the basic magnetism characteristics of magnetic
nanoparticles as well as possess good biocompatibility and biodegradability.
Based on their surface characteristics functionalized nanoparticles can be divided into
three main types; water soluble, oil-soluble, and amphiphilic. Nanoparticles with surfaces
containing hydrophobic group, such as the fatty acid, alkyl phenol are referred to as oil-soluble.
Examples for such surfactants are oleic acid, myristic acid, lauric acid, hexadecylphosphonic
acid, dihexadecylphosphonic acid etc [65,66]. Nanoparticles with chemical groups which are
hydrophilic on the surface are called water-soluble and some examples are citric acid [67],amino
acid [68]. Amphiphilic type refers to the nanoparticles with surfaces containing both hydrophilic
and hydrophobic chemical groups, such as cyclodextrin [69], sulfuric lycine [70] which make the
functionalized nanoparticles both oil-soluble and water-soluble. Polymer coated nanoparticles
are also of great interest for their use in biomedical applications. Polymer coating materials can
be classified into synthetic and natural and some commonly used polymers are listed in Table 1.2
along with their advantages.
Table 1.2: Commonly studied Organic polymers and their advantages.
Polymer
Natural

Dextran

Starch
Chitosan

Synthetic Poly(ethyleneglycol)
(PEG)

Advantages and applications

References

Stability, Biocompatibility, Enables
[15,76-80],
optimum polar interactions with iron oxide
surfaces, Enhances the blood circulation
time.
Improves the biocompatibility, good for
[81,82]
MRI, and drug target delivery
Biocompatible and hydrophilic large
[83-86]
abundance in nature, biocompatibility, and
ease of functionalization. widely used as
non-viral gene delivery system
Enhance the hydrophilicity and water[87-89]
solubility, improves the biocompatibility,
blood circulation times and internalization
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Alginate

Poly-Nisopropylacrylamide
(PNIPAM)
Polyethyleneimine (PEI)

efficiency of the nanoparticles.
Used in target-specific cell labeling,
Magnetic hyperthermia, targeted drug
delivery
Improves
the
stability
and
biocompatibility.
Used in drug delivery applications.
Generally used as thermosensitive drug
delivery and cell separation
Ability to complex with DNA, guide
intracellular trafficking of their cargo into
the nucleus, used for gene delivery cell
transfection with either DNA or siRNA
nucleotides.

[90-92]

[93-96]

[97-100]

Also depending on the properties and the structure, coating arrangement of polymers on
the surface of nanoparticles can be different as well (Fig. 1.4).

Figure 1.4 :Illustration depicting the assembly of polymers onto the surface of magnetic
nanoparticle cores [75].
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Depending on the desired application, these nanoparticle can be further modified by
functionalizing them with various biological molecules such as antibodies, proteins, targeting
ligands, etc. [71-74].These may be bound to the polymer surfaces of the nanoparticles directly or
indirectly by chemically coupling via some functional end groups such as amide or ester bonds
to make the particles target specific. Inorganic materials are used for surface coating of the
nanoparticles, mainly iron oxide nanoparticles. These inorganic materials include silica [101104], metal or nonmetals [105-108] (gold, silver, platinum, palladium, iron, carbon), and metal
oxides (Al2O3) or metal sulfides. The coating with inorganic materials produces “core-shell”
structure with the nanoparticle core and coating shell. These coatings not only provide stability
to the nanoparticles in solution but also help in binding various biological ligands to the
nanoparticle surface. The surface modified magnetic nanoparticles which are stabilized against
clustering and sedimentation, with enhanced biocompatibility can be further modified such as the
addition of specific targeting ligands, dyes or therapeutic agents providing the particles a wide
ranging potential in the biomedical area. Among these various surface modification possibilities
the right choice of functionalization should be carefully chosen to obtain a desired structure
suitable for the intended application.
1.5: Scope of the thesis
This thesis includes the synthesis characterization and two major applications of
superparamagnetic Fe3O4 nanoparticles in the field of biomedicine; magnetic hyperthermia and
drug delivery. Based on the experimental data and analysis on Fe3O4 nanoparticles, we are able
to determine the effect of particle size, polydispersity, anisotropy and dipolar interactions on the
temperature dependent SAR, qualitatively and quantitatively. The cellular studies done on
human pancreatic cancer cells include the cytotoxicity, time dependent cellular uptake and
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distribution of Dextran coated Fe3O4 nanoparticles. A novel drug-dye –nanoparticle conjugation
was designed and fabricated and its cellular entry and time dependent drug release were
investigated as well. Chapter 2 describes the detailed background on nanoparticle magnetism and
magnetic hyperthermia, and their relation to linear response theory. It also provides theoretical
framework used to analyze and interpret the experimental data. Chapter 3 describes various
synthesis methods and functionalization strategies and introduces the working principles of the
key characterization techniques used throughout this research. In Chapter 4, the results of our
investigation on the effect of magnetic dipolar interactions and size distribution of Fe3O4
nanoparticles on temperature dependent magnetic hyperthermia of ferrofluids are discussed.
Chapter 5 explores the effect of Gd-doping and Chapter 6 on the effect of biocompatible coating
of Fe3O4 nanoparticles with dextran and citric acid on magnetic and temperature dependent
magnetic hyperthermia properties. Chapter 7 describes our study on time dependent cellular
uptake and intracellular distribution of dextran coated Fe3O4 nanoparticles functionalized with
fluorescent dye, FITC. Chapter 8 describes our study on the dual conjugation of doxorubicin and
FITC on dextran coated Fe3O4 nanoparticles and its cellular internalization and drug release. The
summary and prospects for future study are described in Chapter 9.
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CHAPTER 2 MAGNETIC NANOPARTICLES AND MAGNETIC
HYPERTHERMIA
2.1: Magnetism in materials
The origin of magnetism in materials is due to both spin and orbital angular momentum
of electrons in atoms/ions/molecules and interactions between them. The magnetic property of a
material is described by a quantity called “magnetization” (M), defined as net magnetic dipole
moment per unit volume of the material. The magnetic response of a material to an external
magnetic field (H) is further defined by Magnetic Susceptibility,
χ = M/H

(2.1)

In the absence of any magnetic ordering, magnetic materials can be divided into two
categories; diamagnetics with small and negative χ (-10-6 to -10-3) and paramagnetic with small
positive χ (10-6 - 10-1). Diamagnetism occurs when the atom has completely filled shells leading
to a zero orbital angular momentum and zero spin. When an external field is applied, it alters the
electron kinetic energy and thus their angular momentum. This leads to a net magnetic moment
opposite to the applied field, while the spin remains zero. On the other hand, in a paramagnetic
material, atoms have a permanent magnetic moment due to the net spin from the unpaired
electrons. In the absence of external magnetic field H, all the magnetic moments are aligned
randomly in different directions due to thermal fluctuation, resulting in a net zero magnetic
moment. However, when an external magnetic field is applied, there will be anon-zero net
magnetic moment, but returns to zero upon the removal of the external magnetic field. The
temperature dependent behavior of paramagnetic susceptibility is explained using the CurieWeiss law [109].
Below a critical temperature, even in the absence of an external field, magnetic materials
can develop long range magnetic order due to exchange coupling of spins (a quantum
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mechanical effect) leading to a non-zero net magnetization. There are three types of basic
magnetic ordering namely, ferromagnetic, antiferromagnetic, and ferrimagnetic. Figure 2.1
shows the three simplest types of magnetic ordering. The critical temperature below which this
long range order presents is known as the Curie temperature (for ferromagnets) or Neel
temperature (for antiferromagnets and ferrimagnets).

Figure 2.1: Arrangements of moments in magnetic systems (a) Ferromagnetic ordering
(b) Antiferromagnetic ordering (c) Ferrimagnetic ordering
It is well known that a bulk ferromagnetic material is composed of magnetic domains,
regions in which all of the local spins are aligned parallel to each other, due to exchange
coupling. The formation of magnetic domains is a result of balancing several energy terms: the
exchange energy which tries to align all the magnetic moment along the same direction, the
magnetocrystalline energy which arises from spin-orbit coupling and energetically favors
alignment of the moments along specific direction, and the magnetostatic energy. The direction
of the ferromagnetic spin alignment varies from one domain to another, and is randomly oriented
in samples cooled through the transition temperature in zero fields so that the net magnetization
is zero or small. The different domains in a ferromagnet are separated by domain walls in which
the magnetization rotates from one direction to another. Magnetic behavior of bulk
ferromagnetic materials is governed by the dynamics of these domains. Unlike the paramagnets,
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ferromagnets will not relax back to zero magnetization upon removal of the external magnetic
field since the domain wall motion process is not reversible which is known as “hysteresis”. One
characterizes this M-H curve using three parameters; the saturation magnetization (Ms), the
coercivity (Hc) and the remnant magnetization (Mr) (Figure 2.2).

Figure 2.2: M-H curve for a collection of ferromagnetic particles showing hysteresis
2.2: Magnetic nanoparticles and superparamagnetism
As mentioned in chapter 1, magnetic nanoparticles refer to materials with size ranging
from few nanometers to several hundred nanometers which are ferromagnetic or ferrimagnetic in
its solid bulk form. As the particle size decreases below a critical value, the formation of domain
walls become energetically unfavorable and particles become single domain particles in which
all the spins are aligned, called “superspins” with a large magnetic moment (~ 10,000 Bohr
Magneton) on each particle. At temperatures above a characteristic temperature, TB, called
Blocking temperature (described in Section 2.2.1), the moments on individual nanoparticles will
tend to align an external applied field, similar to a paramagnetic material, but with a large
magnetization. Figure 2.3 shows magnetic behavior of a collection of such nanoparticles under
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an

external

magnetic

field,

without

any

hysteresis.

This

phenomenon

is

called

“superparamagnetism” and is important to understand the magnetic behavior of nanoparticles.

Figure 2.3: M-H curve for a collection of superparamagnetic nanoparticles
For an assembly of non-interacting superparamagnetic particles, the magnetization (M) as a
function of applied magnetic field (H) is explained by the Langevin function,
1

𝐿(𝑥) = coth 𝑥 − 𝑥

.2)

where x=MsVH/kBT, Ms is the saturation magnetization and V is the volume of the particle given
by V=πD3/6 in terms of diameter of the particle (D). When the particle size distribution is taken
into account the magnetization can be written as,


M (H )  M s

 f ( D)VL( x)dD
0


 f ( D)VdD
0

where f(D) if the log-normal distribution given by,

(2.3)
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f ( D) 
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 D 0  
exp  
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2 D







(2.4)

Here, Do is the most probable particle diameter and σ is the width of the distribution.
2.2.1: Magnetic Anisotropy in Nanoparticles
The magnetic properties of an ensemble of single domain particles are determined by the
thermal energy and the magnetic anisotropy of the particle. In bulk magnetic materials, usually
there is an energetically favorable direction along which the magnetic moments are typically
aligned, referred to as the easy axis. The difference in magnetic energy to produce saturation in a
hard direction is called the anisotropy energy. The most common types of anisotropy that affects
the magnetic behavior of the material are magnetocrystalline anisotropy, surface anisotropy,
shape anisotropy, exchange anisotropy, and induced anisotropy (for example, by stress) [110]. In
nanoparticles, shape, surface and magneto crystalline anisotropies are the most important. Shape
anisotropy arises from the long range dipolar interactions within the particle and causes
magnetization to depend on the shape of the sample. For an example, in long thin needle shaped
particles, it is easier to magnetize along its long axis compared with that along any of its short
axes. A perfectly spherical nanoparticle having symmetry along all possible directions will have
no shape anisotropy. As the size of the nanoparticle decreases, the surface to the volume ratio is
increased and the surface effects become more significant. Therefore surface magnetic
anisotropy is expected to contribute to the total magnetic anisotropy and the effective anisotropy
is given by the following expression [111];
𝐾 = 𝐾𝑉 +

6𝐾𝑆
𝐷

(2.5)
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Where, KV is the magnetocystalline anisotropy constant of the core, KS is the surface anisotropy
energy constant, and D is the size of spherical particles.
Magnetocrystalline anisotropy arises from the symmetry of the lattice, the shape of the
electron orbitals and from spin-orbit coupling. The actual direction of the magnetization can be
either of two opposite directions along the easy axis. More precisely, this represents “uniaxial
anisotropy”, but this is normally sufficient for understanding the magnetic response of
nanoparticles. The magneto-crystalline anisotropy (E) is given by,
E  KVSin 2  

(2.6)

where, K is the uniaxial anisotropy energy density and V is the volume of the particle and  is the
angle between the magnetization and the easy axis. As the particle size is reduced, the anisotropy
energy decreases. In sufficiently small particles, thermal energy KBT is comparable or larger than
the anisotropy energy. If the thermal energy KBT is large compared to the anisotropy energy, the
direction of the nanoparticle moment can flip freely between the two directions defined by the
easy axis. Magnetic moments are randomly oriented leading to a zero net magnetization
behaving as a superparamagnetic system. The relaxation time (), which is the average time it
takes the magnetic moment to jump from one minimum to the other is given by the Neel-Brown
relation:

 KV 

k
T
 B 

   0 exp 

(2.7)

In this equation, τ0is a microscopic time scale for the transitions, which are typically taken to be
10-9-10-13 s, kB is the Boltzmann’s constant and T is the temperature. As the thermal energy of the
particle is reduced by lowering the temperature, the fluctuations slow down and the relaxation
time increases.
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Figure 2.4: (a) Energy barrier between two easy axes in a magnetic nanoparticle (b) (i) at
temperatures below the TB of the particles, the net moments are quasi-static. (b) (ii). At
temperature well above TB, the moment reversals are so rapid that the net magnetic
moment is zero [112].
The critical temperature, at which the relaxation time matches with the experimental
measuring time,τ, is known as the blocking temperature (TB) and is a characteristic of the particle.
The value of τm is given by the type of the measurement being performed. It is typically of the
order of 102 seconds for DC measurements and 10-110-5s for AC susceptibility measurements.
At the blocking temperature,
𝑇𝐵 ≈ 𝐾𝑉 ⁄𝑘𝐵 𝑙𝑛(𝜏𝑚 ⁄𝜏0 )

(2.8)

Below this blocking temperature the spins are frozen over the timescale of each measurement.
Above the blocking temperature, the moments possess enough energy to flip and particles
behave like simple paramagnets. The above ideas are illustrated in Figure 2.4. By measuring the
temperature dependent DC magnetization of the material, the TB can be estimated to determine
the magnetic anisotropy constant, K.
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2.3: Magnetic dipolar interactions
Magnetic dipole interaction between two magnetic dipoles ⃗⃗⃗⃗
µ1 and ⃗⃗⃗⃗
µ2separated by a
distance 𝑟 is described as,
Ed =

µ0
4πr 3

3

[µ
⃗⃗⃗1 . ⃗⃗⃗
µ2 - 2 (µ
⃗⃗⃗1 .r)(µ
⃗⃗⃗2 .r)]

(2.9)

where μ0 is the permeability of free space. The atoms in a crystal have magnetic moment of a
few Bohr magnetons. Therefore magnetic dipole interactions between atoms are very small and
have a negligible influence on the magnetic ordering at finite temperatures compared to
exchange interactions which are responsible for magnetic ordering in materials. However,
ferromagnetic/ferrimaagnetic nanoparticles with dimensions around 10 nm can have magnetic
moments as large as 10,000 Bohr magnetons, and therefore, dipole interactions between
nanoparticles can have a significant influence on the magnetic properties. In a sample of
randomly distributed nanoparticles having an average magnetic moment μ the dipole interaction
µ µ2

0
energy of a particle can be written as, Ed ≈ 4πr
3 [113] .

Over the past years, there are many studies that report the effect of dipolar interactions on
the magnetic properties of nanoparticles. For example, Vargas et al [114]investigated the effect
of dipolar interactions on magnetic properties of Fe based nanoparticles by tuning the strength of
interactions by changing the concentrations of the particles. It is clearly shown that for increasing
the particle concentration, the maximum of the ZFC curve shift to higher temperatures,
indicating an increase in the blocking temperature, TB. A similar trend has been observed in many
reported studies [115,116]. Dormann et al [115], analyzed the frequency dependence of the
blocking temperature for a series of ɤ-Fe2O3 nanoparticles with different strengths of interparticle interactions. He suggests that interparticle interactions simply lead to a progressive
increase of the energy barrier. The model suggested by Dormann is based on a statistical
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calculation of the dipolar energy for a collection of disordered particles with a non-zero size
distribution and easy directions in random orientation. The interparticle interactions are
described by an energy term, Eint with uniaxial symmetry hence added to the anisotropy energy
for the particle alone. This leads to an increase in magnetocrystalline energy barrier, EB, and the
modified relaxation time is given by,
τ𝑁 =τ0 exp [

EB +Eint
K BT

]

(2.10)

This model has been used to explain the similar results observed in other studies such as Fe
particles embedded in an alumina matrix [117], γ-Fe2O3 particles dispersed in a polymer [116],
magnetite particles dispersed in dispersed in calcium silicate glasses [118] and as well as Ni NPs
embedded in an amorphous SiO2/Cmatrix [119].The same observation, the increased relaxation
time with increasing dipolar interactions, is explained by different approach in the study reported
by Landi et al. [120].He defines an effective energy barrier based on a random mean field
approximation. The dipolar interactions produced by an ensemble of particles are interpreted as
random field acting on a reference particle resulting in a new term in the free energy of the
reference particle, expressed as a cumulant expansion of the random field, carried up to fourthorder. In this model, the dipolar interactions increase the effective anisotropy barrier rather than
inciting some degree of order into the system.
In addition to above models, there are other studies that employ Langevin function for
better understanding of the role of dipolar interactions on the magnetic properties of
nanoparticles. This theory, known as T* model, is proposed by Allia et al. [121] in his study on
Granular Cu-Co alloys. He considers the particle moments to be interacting through long range
dipolar random forces and pictures the effects in terms of a temperature T* added to the actual
temperature T in the denominator of the Langevin function argument which explains all features

21
of the experimental M(H) curves. His argument is justified as follows; the direction, sign, and
magnitude of the dipolar field acting on any magnetic moment randomly changes at a
sufficiently high rate which enhance the disorder of magnetic moments. This exerted disorder
opposes the ordering effect of the external magnetic field which is similar to the role played by
the temperature and hence strengthens its effects. The apparent temperature is written as
Ta=T+T*, T* is not an arbitrary quantity, but is related to the rms dipolar energy D through the
relation,  D  kT * .The experimental magnetization M, with modified Langevin function can now
be written as,






M S VH

 f ( D)VL K T  T  dD
*

M (H )  M S

B

0



(2.11)

 f ( D)VdD
0

By fitting the experimental magnetization data to the above expression, an estimation of the
strength of dipolar interaction can be obtained. Even though this model explains the complex,
collective effects of dipolar interactions in a simplified, but effective way, this has some limits
which are addressed as well by the authors. Firstly, the ‘‘interaction’’ temperature T* may be
much higher, larger than the measurement temperature. According to the authors, the T*
obtained by best-fit procedure reflects not only changes in the spatial distribution of particles or
in their degree of correlation, but also the presence of additional interactions among particles
such as indirect interactions of RKKY type which are presence in metallic granular systems.
When T increases towards Tc, T* drops, vanishing when T=Tc. On cooling, the T* becomes
stronger, to finally become dominant without changing the functional form of the M (H) curve.
When the temperature is lowered towards the blocked regime, the moments are expected to be
frozen in random directions. Therefore, the argument of dynamic disorder provided by
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interactions is no longer valid in the blocked regime. But as long as the measurements are taken
at superparamagnetic regime, this model provides adequate understanding of the effects of
dipolar interactions.
2.4. Magnetic hyperthermia and linear response theory
The cyclic increase of internal energy of a magnetic system in adiabatic process is equal
to the magnetic work done on the system and can be expressed as [122]:
∆𝑈 = −𝜇0 ∮ 𝑀𝑑𝐻

.12)

where M is the magnetization and µ0 is the permeability of free space and H is magnetic field
intensity. The power dissipation in the magnetic system during several cycles is equal to the
internal energy multiplied by the frequency, 𝑃 = 𝑈𝑓. As described by Rosensweig [122], the
response of a magnetic system to an alternating external applied magnetic field , H(t) =H0cos(ωt),
where ω is the angular frequency and H0 is the amplitude of the field, can be explained as follows.
The magnetic susceptibility, χac, which describes the full dynamic response of a system to an external
stimulus, can be written in terms of real and imaginary parts,

χ𝑎𝑐 = χ′ − 𝑖χ′′

(2.13)

Therefore, the resulting magnetization, M (t) is,
M(t) = Re(χ𝑎𝑐 𝐻0 𝑒 𝑖𝜔𝑡 ) = 𝐻0 (χ′ cos 𝜔𝑡 + χ′′ sin 𝜔𝑡)

(2.14)

Substituting M and H in Eq.1.14 yields,
2𝜋

∆𝑈 = 2𝜇0 𝐻02 χ′′ ∫0𝜔 𝑠𝑖𝑛2 𝜔𝑡 𝑑𝑡

(2.15)

Integrating the above equation and multiplying the result by the cyclic frequency f =ω/2π gives
the power dissipation,
𝑃 = 𝜇0 𝜋χ′′ 𝑓𝐻02

(2.16)

The frequency dependence of the complex susceptibility is given by the following expression.
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χ=

χ0

(2.17)

1+𝑖𝜔𝜏

The real and imaginary parts of the susceptibility can therefore be expressed as:
χ

0
χ′ = 1+(𝜔𝜏)
2

(2.18)

𝜔𝜏

χ′′ = 1+(𝜔𝜏)2 χ0

(2.19)

Here χ0 is the equilibrium susceptibility, which is expressed as,



1

 0   i  coth   



(2.20)

where χi = (µ0ΦMd2 Vm)/3kBT,initial susceptibility , ξ = (µ0 MdH0Vm)/kBT with Md, the domain
magnetization of the nanoparticle, and Φ is the volume fraction of the magnetic nanoparticles in
the ferrofluid. Under the influence of an external alternating magnetic field, nanoparticles generate
heat due to relaxation losses (Neel and Brownian relaxations) and hysteresis losses. In
superparamagnetic particles, with negligible /zero coercivity, the contribution from the latter is not
significant at all and the relaxation losses are the prominent mechanisms. The relaxation mechanisms
are illustrated in Figure 2.5.

Figure 2.5: Left: Neel relaxation showing the rotation of magnetic moment (white
arrow). Right: Brownian relaxation where the physical rotation of the nanoparticle takes
place to align the moments along the magnetic field [36].
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In case of the Brownian relaxation, heating of the particles in liquid suspension occurs
due to viscous drag between the particles and liquid, where the entire particle physically rotate to
align the magnetic moment with the applied field. The Brownian relaxation time is given by the
equation 2.22,

B 

4 RH3
k BT

(2.21)

Here  is the viscosity of the suspension and RH is the hydrodynamic radius of the surfactant
coated nanoparticle. For Neel relaxation, the moments of the particles fluctuate with the applied
field and the relaxation time is given by the following equation.

N 


2

 KV  KV

k
T
 B  k BT

 0 exp 

(2.22)

Since the Brownian and Neel processes take place in parallel, the combined relaxation of the
particle is characterized by the effective relaxation time eff ,defined as: 1/eff =(1/1/
By substituting the Eq 2.19 in the power dissipation expression given by Eq. 2.16, and taking
the polydispersity of the particles into account by incorporating the log normal distribution given
by Eq.2.4, the temperature dependent power dissipation in the sample can be expressed as,


P(T )  
0

 0  0 H 02
2

 eff

1   eff



2

f ( D) d ( D)
(2.23)

Depending on the value of ωτ , two regime can be identified; the high frequency limit in which
𝜔𝜏 ≫ 1 and the low frequency limit where 𝜔𝜏 ≪ 1.In high frequency limit Eq 2.24 reduces
to the following expression which clearly shows that at higher frequencies the generated
power is independent of the frequency ω.
𝑃 = 𝜇0 𝐻02 χ

1
2𝜏

.24)
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On the other hand, in the low frequency limit where ωτ<< 1, the power is proportional to the
square of the frequency as shown below.
𝑃 = 𝜇0 𝐻02 χ

𝜔2𝜏
2

(2.25)

The linear response theory described above assumes the magnetic response of the system to be
linear with the applied magnetic field. To be more specific this theory is valid in the
superparamagnetic regime where 𝐻0 < 𝑘𝐵 𝑇⁄𝜇0 𝑀𝑠 𝑉 .
Finally, in order to incorporate the dipolar interactions in this model, we replaced the
temperature term T in in the above equations with the apparent temperature (T+T*), as done in the
analysis of M-H data using Langevin model.
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CHAPTER 3 SYNTHESIS AND CHARACTERIZATION
METHODS OF MAGNETIC NANOPARTICLES
3.1: Synthesis of Fe3O4 nanoparticles
Over the past years many research works have been done to develop efficient synthesis
approaches to produce the size/shape controlled, stable, biocompatible, and monodispersed iron
oxide nanoparticles (NPs) [123-126]. The most common methods include co-precipitation
[51,127], thermal decomposition [128], hydrothermal synthesis [129,130], microemulsion [131]
and sonochemical [106] synthesis. The most conventional method for obtaining Fe3O4 or ɤFe2O3 is by co-precipitation which consists of mixing ferric and ferrous salts in highly basic
solutions at room temperature or at elevated temperature. The size and shape of the iron oxide
nanoparticles depends on the type and amount of salt used (Fe2+:Fe3+ ratio), the reaction
temperature, the pH value, ionic strength of the media, and the other reaction parameters such as
stirring rate, dropping speed of basic solution. Co-precipitation method results in the production
of water-soluble magnetic nanoparticles and is relatively cost-effective compared to other
synthesis techniques. However, this method leads to nanoparticles with wide particle size
distribution due to lack of control over hydrolysis reactions of the iron precursors and the
nucleation and growth steps causing a wide range of their blocking temperatures. Thermal
decomposition technique, decomposition of organo-metallic iron precursors at higher
temperatures in organic solvents, involves complicated operation and generates high quality
monodisperse particles because of separate nucleation and growth processes. But the resulting
nanoparticles are hydrophobic and thus cannot be directly used for bio-applications. In order to
make them water soluble, laborious post-synthesis ligand exchange procedures are necessary,
which may result in aggregation and loss of magnetic properties. The other common, recently
developed, method is hydrothermal synthesis which generates nanoparticles with excellent
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crystallinity with controllable size and shape in aqueous phase. The properties of the
nanoparticles can vary with the synthesis method due to the differences in cationic distribution
and vacancies, spin canting, or surface contribution.
For the synthesis of nanoparticles studied in this thesis work, chemical co-precipitation
and hydrothermal method were used as standard methods of synthesis because of the simplicity,
and ability to produce superparamagnetic iron oxide nanoparticles of reasonable size (10-15 nm).
Moreover, these techniques are compatible with different approaches we are using for
functionalizing the nanoparticles.
3.1.1: Co-precipitation synthesis
The reagent precursor chemicals, FeCl24H2O and FeCl36H2O were obtained from
Merck and were used without further purification. Aqueous solutions of FeCl2.4H2O and
FeCl3.6H2O were mixed in 1:2 molar ratios. For a typical synthesis, 5.4 g of FeCl3.6H2O in 20
mL of 2 M HCl was mixed with 2.0 g of FeCl2.4H2O in 5 mL of 2 M HCl in a 1 L beaker. After
stirring the mixture with magnetic stirrer for about 5 min, 250 mL of 1 M NH4OH was added
dropwise into the mixture under constant magnetic stirring, which resulted in a brown precipitate
that became black eventually upon the formation of Fe3O4 nanoparticles (Figure 3.1).
3+

2+

Fe /Fe
solution

NH4OH

Washed x10
Figure 3.1: Synthesis of Fe3O4 nanoparticles by chemical co-precipitation technique.
The chemical reaction may be written as follows;
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𝐹𝑒 2+ + 2𝐹𝑒 3+ + 8OH − → 𝐹𝑒3 𝑂4 + 4𝐻2 𝑂 + 8𝐻𝐶𝑙
The nanoparticles were stirred for another 10 minutes, isolated with a magnet and washed
several times with deionized water until a neutral pH was reached which was confirmed by a
litmus paper.
The particle size of the nanoparticles obtained from the co-precipitation method can be
varied in the range of 6-13 nm by changing the different experimental parameters such as the
RPM rate, rate of adding the base to the reaction mixture, concentrations of the salts and the base
etc. For example, using 2 M NH4OH added rapidly to the reaction mixture under 1000 rpm of
stirring rate resulted in generating nanoparticles of 6-7 nm size whereas using 1 M NH4OH
added dropwise to the reaction mixture under a stirring rate of 350rpm produces 11-12 sized
nanoparticles.
3.1.2: Hydrothermal synthesis
The Hydrothermal synthesis of Fe3O4 nanoparticles was carried out by precipitating
FeCl2.4H2O and FeCl3.6H2O (1:2 molar ratio) in alkaline medium (NH4OH) followed by the
hydrothermal treatment. 2.0 g of FeCl2.4H2O and 5.4 g of FeCl3.6H2O were mixed in 50 ml of
2M HCl solution 10 ml of NH4OH solution was then added dropwise into the mixture under
constant magnetic stirring. After 10 minutes of stirring, the mixture, which contains the
precipitated black product, was immediately added into a Teflon-lined stainless steel autoclave
with 60 ml capacity and subsequently placed in a furnace at 134 °C for 1 h. The autoclave was
cooled naturally after the hydrothermal treatment and the precipitate was recovered and washed
several times with DI water by means of a magnet.
After the synthesis of the nanoparticles they were washed to remove the excess ions
which resulted in wet slurry. Several portions of the slurry were then used to quantify the amount
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of iron oxide in each gram of the slurry. This estimation was used to determine the concentration
of the prepared ferrofluid. This method of calibration at the beginning of the preparation of the
ferrofluid, provides an accurate method of reporting the concentration of the ferrofluid with a
narrow window of uncertainty.
3.2: Surface functionalization of Fe3O4 nanoparticles
In our research, we used dextran, a natural polysaccharide, and citric acid for the
preparation of ferrofluid. Both the materials have different moieties which allow us the further
functionalization with anti-cancer drugs, dyes and targeting ligands. Dextran has the hydroxyl
groups which could be attached to the amine group or concerted into carboxyl groups whereas
citric acid contains carboxyl groups providing many possibilities of functionalization.
3.2.1: Dextran coated Fe3O4 nanoparticles
In order to coat the Fe3O4 nanoparticles with dextran, synthesized nanoparticles (from the
wet slurry)and 60-90 kDa dextran (1:1 wt.) were dispersed in 25 ml of 0.5 M NaOH separately.
The dextran solution was kept under sonicating and the iron oxide nanoparticles solution was
added drop wise into the dextran solution over 30 minutes period. The resulting mixture was
sonicated for 24 hours to get the well suspended ferrofluid which was stable over 6 month’s
period.
3.2.2: Citric acid (CA) coated Fe3O4 nanoparticles
Citric acid stabilized nanoparticles were prepared by direct addition method [132].
Simply, 5ml of 0.1mg/ml citric acid solution was added to 0.5g of Fe3O4 nanoparticles dispersed
in 20ml of 0.5 M NaOH solution. The mixture was heated to 90 ºC and stirred for 60 minutes.
After that the solution was cooled down to room temperature and was dialyzed using 8-10 kDa
cutoff membrane to remove excess citric acid.
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3.2.3:Cross-linking of Fe3O4 nanoparticles
Cross-linking of Dextran coated Fe3O4 nanoparticles, which endows a greater stability of
nanoparticles, was carried out using an established published procedure [80]. Dextran coated
Fe3O4 were cross-linked using epichlorohydrin (ECH). The solution containing 1 ml of dextran
coated Fe3O4 nanoparticles; 5 ml of 5 M NaOH, 2 ml of DI water and 2 ml of ECH was
prepared. The mixture was incubated at room temperature with continuous shaking to promote
the interaction between aqueous and organic phase. After 24 hours of incubation, the black
colloidal suspension was dialyzed several times against DI water to remove the excessive ECH
and ions.
3.2.4: FITC functionalized Fe3O4 nanoparticles
Fluoro isothiocyanate (FITC) is a widely used fluorescent dye, frequently used for
cellular imaging. The functional group of FITC, isothiocyanate group, is reactive towards amine
group which makes it possible for conjugation. To graft the surface of Fe3O4nanoparticles with
required amine group, 1.25 ml of concentrated NH4OH was added to the cross linked Fe3O4
nanoparticles solution and the mixture was left for continuous sonication overnight. To label
dextran coated Fe3O4 with FITC, 1 ml of 0.01 M FITC (10 μmol) in phosphate buffer saline
(PBS) at pH 7.4 was added to 1 ml of amino functionalized cross linked Fe3O4. The mixture was
allowed to stand for 1 hour at room temperature and excess FITC was removed by dialysis.
3.3: Cell culture protocol
All the in-vitro cell studies done in this research were conducted on human pancreatic
cancer cells, Mia PaCa 2.The cell culture experiments were carried out inside a cell culture hood.
MIA PaCa-2 human pancreatic cancer cells were cultured on poly L-lysine-coated petri
dishes in Cell Growth Medium (CGM) made of Dulbecco’s modified essential medium (DMEM)
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containing 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin. To continue the cell
line, the confluent plate is split and cells are re-cultured on a new plate as described below. Cell
culture plate which was stored in the incubator was taken out and growth media was carefully
aspirated. The cells were washed twice with 10 ml of sterile 1X phosphate buffered saline (PBS)
at pH 7.4 followed by exposure to 0.25% trypsin in PBS for 3-4 minutes inside the incubator
which detaches the cells from the surface of the plate. CGM was then added to terminate the
trypsin activity. The resulting cell suspension was centrifuged for 4 minutes at 1,500 rpm (300g),
and the pellet re-suspended in 6 ml of cell growth medium. Then 1 ml of this suspension was
added to a new culture plate containing 9 ml of fresh CGM. To keep the cells healthy splitting
was done twice a week.
3.4: Structural characterization methods
In order to confirm that the synthesized samples have the required properties for intended
applications we have utilized different characterization techniques as described in the rest of the
chapter. X-ray diffraction is mainly and commonly used to identify the crystal structure of the
material, to estimate the crystalline size and to identify the crystalline impurities in the sample
whereas transmission electron microscopy is a great tool to investigate the morphology and
determine the particle size distribution accurately. Colloidal parameters such as hydrodynamic
size and zeta potential are determined using dynamic light scattering.
3.4.1: X-ray diffraction (XRD)
X-rays are electromagnetic radiation with the wavelength of 0.01 to 10 nm corresponding
to energies in the range of 100 eV to 100 keV. X-rays with short wavelengths that are
comparable to the size of atoms can be used to probe the arrangement of atoms and molecules
inside the crystalline materials. Generally, Cu and Mo targets are used in diffractometers which
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produce x- rays of wavelength 1.54 Å and 0.8 Å respectively. When x-rays interact with atoms
of the materials, waves diffracted from different layers of atoms interfere with one other to
produce sharp maxima in the intensity (constructive interference) if atoms are arranged
periodically (Figure 3.2).The basic principle of XRD is described by Bragg’s Law,
2𝑑(ℎ𝑘𝑙) sin 𝜃 = 𝑛𝜆

(3.1)

where, d (hkl) is the spacing between the atomic planes with the Miller indices hkl, θ is the angle
between the incident rays and the atomic planes, n is any positive integer and λ is the wavelength
of the incident rays.

Figure 3.2: The diffraction of x-rays from atomic planes
A typical powder x-ray diffractometer consists of an x-ray source, a sample stage, a
detector. The x-ray is focused on the sample at an angle θ, while the detector opposite the source
reads the intensity of the x-ray it receives at 2θ away from the source path (Figure 3.3). The
incident angle is increased over time always keeping the detector angle 2θ above the source path.
For our XRD measurements nanoparticle powder samples, we used a Rigaku MiniFlex 600 Xray diffractometer with a θ-2θ scanning mode operating at a voltage of 40 kV and current of 150
mA. The average crystalline size of the particles, davg, can be estimated by the Debye-Scherrer
equation,
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𝑑𝑎𝑣𝑔 = 𝛽

𝑘𝜆

𝐹𝑊𝐻𝑀 cos 𝜃

(3.2)

where, λ is the x-ray wavelength, k is the shape factor which is roughly equal to 0.94 for
spherical particles, βFWHM is the full width at half mamixa measured in radians and θ is the
diffraction angle.

Figure 3.3: The powder x-ray diffractometer geometry
3.4.2: Transmission electron microcopy (TEM)
TEM is a powerful imaging tool used in medical, biological, and materials research. The
basic principle of operation is similar to that of optical microscope, the difference being that
TEM uses electrons instead of light. The wavelength of the electrons is much smaller (in the
order of 10 to 100 pm) than the wavelength of light hence its resolution is many orders of
magnitudes higher than an optical microscope which allow us to “see” the particles sized in nano
range. The electrons that are emitted from an electron gun at the top of the microscope travel
through the vacuum in the column of the microscope. This traveling electron beam is focused
into very thin beams by means of electromagnetic lenses and the concentrated beam is then
incident on the thin sample specimen of interest. These electrons are absorbed, scattered and
transmitted through the sample. Transmitted electrons strike the fluorescent or photographic
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screen at the bottom of the microscope generating a shadow image of the specimen which is
visualized by means of a sophisticated camera. These images contain useful information about
the morphology and crystal structure of the sample. A JEOL 2010 FasTEM transmission electron
microscope operated at 200 kV was used to obtain the TEM images of our nanoparticles. The
sample preparation for TEM was done by mounting one or two drops of diluted solution of
nanoparticles dispersed in ethanol on a carbon coated copper grid followed by drying.
3.4.3: Dynamic light scattering (DLS)
Dynamic light scattering and photon correlation spectroscopy are widely used to
determine the hydrodynamic size and size distribution of colloidal particles. When a
monochromatic beam of light, such as laser, passes through a solution, time dependent
fluctuations in the intensity of scattered light occur due to the Brownian motion of the particles
in the solution. An autocorrelation analysis of these intensity fluctuations provides an estimation
of the diffusion coefficient (D) which relates to the hydrodynamic size or diameter, dH, The
autocorrelation function is given by a single exponential function, where A is the baseline at
infinite decay and β is the amplitude at zero decay.
𝐶(𝜏) = 𝐴 + 𝛽𝑒𝑥𝑝(−2𝜏Γ)

(3.3)

The above equation can be used to determine Γ which relates to the diffusion constant D
through 𝐷 = Γ⁄𝑞 2 where q is the scattering wave vector, a quantity that is related to the
scattering angle, wave length of the laser and the refractive index of the solution. The
hrdrodynamic size or diameter, dH , can be then estimated using Stokes-Einstein relation (Eq
3.4),
𝑘 𝑇

𝐵
𝐷 = 6𝜋𝜂d

𝐻

(3.4)
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η, kB,T being the viscosity of the medium, boltzman constant and absolute temperature
respectively.
Both the hydrodynamic size distribution and zeta potential measurements (described in
the next section) were done using a Nano ZS90 (Malvern Instruments). Ferrofluids were diluted
using DI water and the pH of the dilute solution was measured using pH meter. The
concentration of the nanoparticle dispersions used for these measurements was kept in the range
of 50-100 µg/ml.
3.4.4: Zeta potential measurements
The particles in a colloidal suspension carry an electrical charge and the amount of
charge on the particle surface is an important characteristic which determines stability of the
particles in a suspension. This surface charge creates a countercharge in the surrounding solution
screening the electric surface charge forming an electrical double layer. The magnitude of the net
electric charge in this screening diffused layer is equal that of net surface charge, but has the
opposite polarity. As a result the overall structure is electrically neutral. The charges on the
particle surface are normally considered to be attached rather firmly and the outer boundary of
this layer is defined as the Stern layer. The surrounding charge, by contrast, is much more
loosely associated with the particle and diffuses with the charged particle. The boundary of this
layer is defined as the slipping plane (Fig. 3.4). The electrostatic potential changes very quickly
(and linearly) through the surface- layer whereas it changes more or less exponentially through
the diffuse layer. The charge or electrostatic potential at the slipping plane is defined as the zeta
potential (ξ) and is the key indicator of the stability of colloidal suspensions. It depends on the
properties of the dispersive medium such as pH as well as on properties of the surface.
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Electrostatic repulsion between particles depends on the value of zeta potential hence higher the
absolute value of the zeta potential would lead to a more stable the system.

Figure 3.4: Distribution of charges around a charged particle in a colloidal suspension
3.5: Magnetic characterization
The magnetic properties (saturation magnetization, magnetic core radius, coercivity, etc.)
of the synthesized powder as well as the ferrofluid samples were determined using a Quantum
Design Model 6000 Physical Property Measurement System (PPMS). It can be used to take
measurements in the temperature range from 1.8 to 400 K with magnetic fields up to 9 T. The
PPMS consists of a cryostat unit having superconducting magnetic coil. The sensitivity of AC
and DC measurements are 10-8 and 10-5 emu, respectively. Sample preparation for the
measurements of powder samples was done as follows: Approximately, 20-30 mg of
nanoparticles was placed in a gelatin capsule, packed with cotton to restrict the motion of the
sample and mounted in a straw with proper stitching. For the ferrofuid samples, we used a sealed
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liquid sample holder purchased from Quantum Design. However using this holder limits our
ferrofluid measurements at 300 K.
In order to investigate the dynamic relaxation of the synthesized particles, AC
magnetization measurements on the powder samples under a 10 Oe excitation were taken in the
entire temperature range T = 10 K to 300 K using PPMS .The measurements were done at
different frequencies ranging from 350 Hz to 2000 Hz.
3.6: Magnetic hyperthermia measurements
The schematic of experimental set up for a typical hyperthermia set up (Fig. 3.5.a) consist
of a parallel LC tank circuit. The coil carrying the current provided by the amplifier essentially
acts as an inductor of inductance L. It is connected to a capacitor of capacitance C and this
arrangement generates and oscillating magnetic field of a particular frequency. The ferrofluid
sample is positioned inside the coil with an insulation cover to prevent heat exchange with the
surroundings (adiabatic system). For the magnetic hyperthermia measurements, we used an
Ambrell Easy heat station coupled with a solenoid (Fig. 3.5.b).

Figure 3.5: (a) The experimental set up for a typical hyperthermia set up (b) Ambrell
Easy Heat System and OPTOCON fiber optic thermometer. The coil, sample holder and
insulating cotton padding are shown as well.
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The temperature of the sample was measured using an Optocon P/N FOTEMP1-OEM fiber optic
thermometer interfaced to the computer for automatic data collection every 2 or 5 seconds. The
current passing through the circuit gives estimation on the amplitude of the magnetic field while
the values of L and C determine the magnitude of the frequency. The higher SAR value can be
achieved by increasing the amplitude (H) and frequency (f) of the applied field. But to prevent
unwarranted side effects and nerve stimulation, magnitude and frequency need to be within
safety limit set to H. f=5×10 -9 Am-1s-1. Therefore, all our measurements had been recorded under
ac magnetic field amplitude of 235 Oe and at a frequency of 375 kHz which are within the
required limit.
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CHAPTER 4 EFFECT OF MAGNETIC DIPOLAR
INTERACTIONS ON TEMPERATURE DEPENDENT
MAGNETIC HYPERTHERMIA IN Fe3O4 FERROFLUIDS
4.1: Introduction
As described in the earlier chapters, superparamagnetic Fe3O4 nanoparticles have
attracted a great deal of attention because of their potential applications in biomedicine and
Magnetic hyperthermia (MHT) is one of the extensively studied applications. In MHT an
external alternating magnetic field is applied to a tissue containing MNPs, which serve as the
heat centers producing heat by relaxation losses thereby heating the tissue. As the MHT can be
used for heating small regions selectively, it offers the potential for being highly selective and
non-invasive technique for therapeutic treatment of cancers and as a consequence it has
advantage over other treatment methods such as chemotherapy and radiation therapy.
Specific absorption rate (SAR), which measures the efficiency of heat generation,
depends on magnetic properties of the particles such as saturation magnetization, magnetic
anisotropy, particle size distribution, magnetic dipolar interactions, and the rheological properties
of the target medium. Therefore, the applications of the Fe3O4 nanoparticles often require
controllable synthesis methods to produce particles with desired size, shape and magnetic
properties. Different synthesis methods often yield systems consisting of polydisperse ensemble
of MNPs of different sizes as seen in transmission electron microscopy (TEM) images, with size
distribution usually describable by a log-normal distribution function. MHT investigations are
often done on colloidal suspensions of MNPs, called ferrofluids, where the nanoparticles are
coated with surfactants to avoid agglomeration and minimize the effects magnetic dipolar
interactions. Some ferrofluid preparations yield a mixture of isolated nanoparticles and
nanocluseters [133], with varying degree of magnetic dipole-dipole interactions present in
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ferrofluids. It is shown that the dipolar interactions among the MNPs affects the SAR value
drastically hence that can be exploited to optimize SAR [133-136]. For a nanoparticle system
consisting of polydisperse particles, a phenomenological theory was proposed to take into
account the effects of magnetic dipolar interactions resulting from the magnetic
moments/superspins of the superparamgnetic nanoparticles [121]. In this, so called the T* model,
dipolar interaction is taken into account by replacing the temperature, T, appearing in the
argument of the Langevin function, by T + T*, where T* is a phenomenological parameter. The
model was used to explain all the features of the observed M vs. H curves in granular Cu-Co
alloys. Effects of dipolar interactions on SAR for a collection of monodisperse MNPs has been
described Landi [120,135] by using mean-field approximation by modifying the relaxation time.
As mentioned earlier, synthesis method is a key factor that determines the properties of the NPs.
Over the years, many methods have been developed for synthesizing size/shape controlled,
stable, biocompatible iron oxide nanoparticles as described in Chapter 3.
In this study, we have synthesized Fe3O4 nanoparticles using two different synthesis
methods: co-precipitation (CP) and hydrothermal (HT) techniques, yielding very similar x-ray
crystallite size ~ 12 nm, which were coated with dextran to obtain a well suspended,
biocompatible ferrofluids. We noted that both CP and HT prepared ferrofluids show very similar
saturation magnetization ~ 70 emu/g and yet exhibit very different SAR values of ~ 110 Watt/g
and 40 Watt/g, respectively, at room temperature. We explain this observed reduction in SAR
value by taking into account the dipolar interactions, using the phenomenological T* model
(Chapter 2.3), to fit the observed M vs. H data using Langevin function, and the temperature
dependent SAR data using linear response theory. The values of the magnetic anisotropy
constant, obtained as a fitting parameter in the temperature dependent SAR calculations, are in
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good agreement with the values determined by frequency dependent magnetic susceptibility vs.
temperature data of powder samples.
4.2: Experimental details
Preparation of the Fe3O4 nanoparticles by CP and HT method was done using procedure
described in chapter 3. The synthesized nanoparticles were coated with dextran to obtain well
suspended ferrofluid following the experimental procedure described in section 3.2.1.
The x-ray diffraction patterns of Fe3O4 nanoparticles (CP and HT) were measured with a
Rigaku MiniFlex 600 x-ray diffractometer using CuKα radiation. Transmission electron
microscopy images were obtained using a JEOL 2010 transmission electron microscope (TEM).
The samples for TEM imaging were prepared by suspending the magnetic nanoparticles in water
followed by sonication for several minutes and adding a drop of that solution onto a carboncoated TEM copper grid and subsequently drying in air. The magnetic properties of ferrofluid
samples were investigated by measuring M vs. H curves at 300 K using a Physical Property
Measurement System (PPMS). We also measured both frequency (350 Hz to 2000 Hz) and
temperature dependent (10 K to 300 K) magnetic susceptibility curves of powder samples at a
field amplitude of 10 Oe to investigate their blocking behavior.
The magnetic hyperthermia measurements were carried out using an Ambrell Easy Heat
system, which consists of a simple solenoid, a capacitor and a power amplifier as described in
chapter 3. Small glass vials were used to hold the ferrofluid samples and the vials were padded
with a cotton sleeve to minimize the heat loss to the surrounding. The magnetic hyperthermia
measurements were made by applying an ac magnetic field of amplitude 240 Oe (19.1 kA/m) at
375 kHz. The temperature of the sample was monitored using an Optocon P/N FOTEMP1-OEM
fiber optic thermometer, which was inserted through a small hole at the center of the top cover of
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the vial to make contact with the ferrofluid. The thermometer was connected to a computer and
the heating curve (temperature vs time) readings were logged at a regular interval of 2 s. To
account for the heat loss to the environment the cooling curves were recorded immediately after
the magnetic field was turned off, as described elsewhere (chapter 3).
4.3: Results and discussion
The XRD patterns of the as-prepared CP and HT Fe3O4 nanoparticles are shown in Fig.4.1.

Figure 4.1: X-ray diffraction patterns of as prepared Fe3O4 nanoparticles (a) by
hydrothermal (HT), and (b) by co-precipitation (CP) methods.
All the observed peaks in the diffraction patterns are consistent with those of standard XRD
pattern of Fe3O4 (reference JCPDS No. 82-1533) confirming cubic crystalline structure and the
absence of any impurities within the XRD detection limits. The average crystallite size of the CP
and HT samples using Debye-Scherer equation was determined to be 11.7±0.6 nm and 11.8±0.5
nm. TEM images (Fig. 4.2) clearly show that the samples contain nearly spherical particles with
a distributed particle sizes (polydispersed).
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Figure 4.2: TEM images of the as prepared Fe3O4 nanoparticles prepared by (a) CP
method, (b) HT method, and their histograms of the particle size distribution. The solid
lines in the histograms represent the log-normal fits.
The particle size distributions of two samples were determined by measuring the sizes of
at least 200 particles from the TEM images and fitting the histogram with a log-normal

 ln( D / D ) 2 
exp 
distribution function, Eq.2.4, f ( D) 
 , where, Do is the most
22
2 D


1

probable particle diameter and is the width of the distribution. The histogram and the lognormal fits are shown in Fig. 4.2. Interestingly, the average particle sizes of the CP and HT
nanoparticles are calculated to be 13.8±3.1 nm and 14.6±3.6 nm, which are slightly larger than
their corresponding estimated XRD crystallite sizes. The previous studies done on Fe3O4
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nanoparticles also have reported a larger TEM size than their XRD crystallite size similar to this
observation [133], and the observed difference is attributed to existence of an amorphous layer of
1-2 nm thickness on the surface of the nanoparticles [137].
Figure 4.3 shows the field dependent DC magnetization, M(H), curves of CP and HT
prepared Fe3O4 nanoparticle ferrofluids at room temperature.

Figure 4.3: Room temperature M vs. H curves of the ferrofluid samples of Fe3O4
nanoparticles prepared by CP and HT methods. The solid lines are the theoretical fits.
Both the systems show superparamagnetic behavior with zero coercivity and a very
similar saturation magnetization of ~ 70 ± 2 emu/g. This value is lower than the value reported
for bulk Fe3O4 ~ 92 emu/g, which is attributed to the surface disorder such as the existence of
magnetic dead layer, spin canting at the particle surface or the spin-glass like behavior of the
surface spins modifying the anisotropy and the magnetic moments of the surface atoms
[138,139]. It has also been shown in the literature that the saturation magnetization of the
particles, in general, increases with the crystallite size [140]. The observation of similar value of
saturation magnetization in our CP and HT samples is consistent with our XRD/TEM results
showing similar crystallite/physical size.
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However, the M (H) curves differ at lower fields (see Fig. 4.3), perhaps indicative of a
difference in magnetic core size distribution. Assuming the superparamagnetic particles are noninteracting, M-vs-H data can be fitted using Eq. 2.3,


M (H )  M s

 f ( D)VL( x)dD
0


 f ( D)VdD
0

Using the particle size (Do) and the width of the distribution () as fitting parameters, we
found the best fitting yielded the average particle diameters to be 10.8±2.0 nm and 7.6±3.2 nm
for CP sample and HT samples. However, these parameters are not consistent with the measured
values from XRD analysis and in particularly, the deviation is significant for the HT sample. We
attribute this discrepancy due to the presence of magnetic dipolar interactions among
nanoparticles in the ferrofluid samples. We have accounted for the dipolar interactions by
introduced a phenomenological temperature, T*, in the modified the Langevin function,

L( x)  coth x 

M sVH
1
, with x 
as described in section 2.3. The solid lines in Fig. 3
x
k B (T  T  )

show the best fits for CP and HT ferrofluids using the modified Langevin function in Eq. (2), and
using T* as an additional fitting parameter while constraining the average particle diameter close
to their XRD crystallite size. Table 4.1 gives a summary of the fitting parameters.
Table 4.1: Fitting parameters obtained from the Langevin fitting for CP and HT ferrofluid
samples
Sample

D0 (nm)

λ

T* (K)

Davg (nm)

CP-Ferrofluid

10.6
11.6
7.0
10.9

0.19
0.19
0.40
0.35

0
70
0
550

10.8 ± 2.1
11.8 ± 2.3
7.6 ± 3.2
11.6 ± 4.2

HT-Ferrofluid

46
Clearly, the M (H) fitting shows the presence of dipolar interaction in both samples with
interaction being much stronger in HT sample compared to the CP sample. Nanoparticles in CP
ferrofluid exhibit nearly non-interacting superparamgnetic behavior with a smaller T* ~ 75 K,
corresponding to an interaction energy of ~ 6 meV. One would expect this as the nanoparticles
are small and are coated with polymer surfactants which form a thick layer on the particles
increasing the interparticle distance (hydrodynamic size ~ 100 nm) in ferrofluid, resulting in
decreased dipolar interactions. On the other hand, HT sample shows an order magnitude higher
T* value compared to the CP sample indicating the presence of strong dipolar interactions
among nanoparticles in HT ferrofluid. We also notice that the polydispersity in the particle size
is much broader in HT prepared samples. We believe that the HT method of synthesis which
involves heating at 140 oC leads to particle agglomeration and an increased fraction of clustered
nanoparticles in the surfactant coated ferrofluid particles.
The results of magnetic hyperthermia measurements of CP and HT ferrofluid samples are
shown in Fig. 4.4 with the inset showing the heating curves. Specific absorption rate, (SAR), of
the ferrofluid samples were determined according to, [122]

SAR (T ) 

M sample  T 
C

m Fe3O4  t  T

where, Msample is the mass of the sample, mFe3O4

(3)

is the mass of Fe3O4 nanoparticles in the

 dT 
sample, C is the specific heat capacity of the sample, and 
 is the time rate of change of
 dt  T

temperature at T. The details of the measurements of heating and cooling curves, and the
analyses of data to extract the temperature dependant SAR by fitting the heating and cooling
 dT 
curves to obtain 
 as a function of temperature is reported in Nemala et al [137]. The heat
 dt 
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capacity of the sample was assumed to be close to that of the carrier liquid (water) due to low
concentration of nanoparticles in the samples. Clearly, the SAR data of the two samples are
strikingly different although they both have similar average particle size. As discussed below, we
have used the linear response theory to fit the entire temperature dependent SAR using the T*
model to take the dipolar interactions into account and investigate the effect of magnetic
anisotropy as described below.
For an ensemble of polydisperse particles, the temperature dependent average power
dissipation in the sample isgiven by the Eq.4.3,


P (T )  

 0  0 H 02

0

2

 eff

1   eff



2

f ( D) d ( D)

(4.3)

Here, Ho and ωare the amplitude and angular frequencyof the applied ac magnetic field, o is the
vacuum permeability. eff

is effective relaxation time involving Néel relaxation, Brownian

relaxation times and o is equilibrium susceptibility and defined as
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dipolar interactions are taken into account using T* model, the Néel and Brownian relaxation
times can be modified as  B 
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these expressions, is the viscosity of the suspension and RH is thehydrodynamic radius of the
coated nanoparticle, K is the anisotropy constant, Vm is the magnetic volume of the nanoparticles,


1
τo ~ 10-9s and T is the sample temperature.o is given by  o   i  coth    , where,


i 

 M d2 H Vm
3k b (T  T )


, is the initial susceptibility,     M d H V m where Md, the domain
k b (T  T )

magnetization of the nanoparticle, and  is the volume fraction of the magnetic nanoparticles in

48
the ferrofluid. SAR in units of W/g is obtained using Eq. (4) as P (T ) / mFe3O4 , where, mFe O is the
3

4

mass of Fe3O4nanoparticles in ferrofluids. The results of magnetic hyperthermia measurements
of CP and HT ferrofluid samples are shown in Fig. 4.4 with the inset showing the heating curves.

Figure 4.4: Temperature dependent specific absorption rates (SAR) estimated for CP and
HT ferrofluid samples of 12mg/ml concentration at 375 kHz ac field of amplitude 235
Oe). The fitted data are represented by the black line. Inset shows the obtained heating
curves for two samples.
Clearly, the SAR data of the two samples are strikingly different although they both have
similar average particle size. The solid lines in Fig. 4 are the best fits to the experimental SAR
data using Eq. (4), the particle size distribution parameters and T* values given in Table 4.1, and
treating the anisotropy constant, K, as a fitting parameter. The SAR fitting yields similar
anisotropy constants for HT (~ 26 kJ/m3) and CP (~ 22 kJ/m3) ferrofluid samples. Clearly, the
dipolar interactions play an important role in magnetic hyperthermia and reduce the value of
SAR.
We have generated SAR (room temperature) curves with and without the dipolar
interactions. Figures 4.5 and 4.6 show the simulated SAR as a function of particle size (Do) using
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Eq. (4.3), and obtained from the M (H) fitting (Table 4.1), and the K obtained from the fitting
the experimental SAR data (Fig. 4.4).

Figure 4.5: Theoretically generated SAR as function of particle size (Keff = 22 kJ/m3 and
 = 0.19) using Eq. (4) for the CP ferrofluid with and without the dipolar interaction. The
symbol represents the experimental value for the CP ferrofluid, showing SAR would be
higher in the absence of dipolar interactions for the same particle size distribution.

Figure 4.6: Theoretically generated SAR as function of particle size (Keff = 26 kJ/m3 and
 = 0.35) using Eq. (4) for the HT ferrofluid with and without the dipolar interaction.
The symbol represents the experimental value for the HT ferrofluid, showing SAR would
be much higher in the absence of dipolar interactions for the same particle size
distribution.
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The calculations show that SAR increases with increasing particle size showing a peak at a
critical size, beyond which SAR decreases with increasing particle size. Further, the peak in SAR
shifts to higher particle size when the dipolar interactions are included in the simulation, and the
curve becomes positively skewed as the value of increases (Fig. 4.6). For our CP sample, the
particle size is below the critical size and the dipolar interactions reduce SAR value by a small
amount (Fig. 4.5).
On the other hand, although the HT sample has a somewhat larger value of K, the peak
SAR value is smaller (Fig. 4.6) than that of the CP sample (Fig. 4.5). This is attributed to much
larger size distribution (of MNPs in HT sample. When the dipolar interactions are introduced
for this sample, the SAR value decreases further making it even smaller compared to that of the
CP sample. We also note that the HT prepared particles have their size very close to the critical
size needed to produce the maximum SAR, but the dipolar interactions reduce their magnetothermal heating efficiency.
To understand the dynamic relaxation of the CP and HT prepared nanoparticles and to
independently determine their effective magnetocrystalline anisotropy, we have measured the ac
susceptibility of the powder samples as a function of temperature at different frequencies ranging
from 350 Hz to 2 kHz. Figure 4.7 shows the imaginary part, ′′, of the ac susceptibility vs.
temperature data for the samples. The ac magnetization curves of HT sample are broader
compared to those of the CP samples, indicating a wider size distribution in the former sample.
This is also in agreement with the magnetization data as discussed earlier. Further, the data
clearly shows that the blocking temperature, TB, is frequency dependent and shifts towards
higher temperatures with increase in frequency in both CP and HT samples implying thermally
activated blocking process. The frequency dependence of TB for a collection of non-interacting
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Figure 4.7: Temperature dependent out-of-phase susceptibility of powder samples at
different frequencies (closed circles represent the data for CP sample and the open circles
represent HT sample data). HT data has also been measured at 2 kHz in addition to the
frequencies mentioned and the data is shown.

 KVm
particles is given by the Néel-Brown model given by equation 2.7,    0 exp 
 k BTB


 described in


Section 2.2.1. In the absence of an external field, KVm is the energy barrier for the reversal of the
magnetic moment. For a system of particles with dipolar interactions the energy barrier can be
replaced by an effective anisotropy energy barrier, Eeff = Keff <Vm>. Figure 4.8 shows the plots of
ln () versus 1/TB for the two samples exhibiting the linear behavior. The results of the analyses
are given in Table 4.2. The observed linear relationship with o ~ 10-9 s imply that Néel model
correctly describes the superparamagnetic behavior of these MNPs. We note that the anisotropy
energy barrier is somewhat larger in HT prepared sample compared to that of the CP sample due
to the presence of strong dipolar interactions. It is gratifying to note that the anisotropy constant
determined from the ac susceptibility measurements are in close agreement with those
determined from the hyperthermia measurements.
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Figure 4.5: The plot of ln () vs. 1/TB for the CP and HT Fe3O4 powder samples.
Table 4.2: Estimated values of magnetic anisotropy constant from the plot of ln () versus 1/TB
Sample

o (s)

Keff <Vm> (J)

Keff (kJ/m3)

CP-Powder

4.5 ×10-9

2.410-20

25.2± 4.3

HT-Powder

1.4 ×10-9

2.910-20

24.9± 4.2

4.4: Conclusions
In summary, we have prepared Fe3O4 nanoparticles by two different methods, coprecipitation (CP) and the hydrothermal (HT) synthesis and measured their magnetic and
magnetothermal properties. Although both the samples have similar particle size (~ 12 nm) and
saturation magnetization (~ 70 emu/g), yet they show drastically different heating rates (SAR) at
room temperature ~ 110 W/g (CP sample) and ~ 40 W/g (HT sample). We have explained this
observed reduction in SAR by taking into account the dipolar interactions and the distribution of
magnetic core size of MNPs in ferrofluids. The HT ferrofluid shows nearly an order of
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magnitude higher effective dipolar interaction and a wider distribution of magnetic core size of
MNPs compared to that of CP ferrofluid. We have fitted the temperature dependent SAR data
using linear response theory, incorporating an effective dipolar interaction, to determine the
magnetic anisotropy constant of the magnetic nanoparticles prepared by CP (22 ± 2 kJ/m3) and
HT (26 ± 2 kJ/m3) synthesis methods. These values are in good agreement with the magnetic
anisotropy constant determined using frequency and temperature dependent ac magnetic
susceptibility data obtained on the powder samples. Based on the analyses of the experimental
data, we conclude that the HT method of synthesis leads to clustering of nanoparticles with
strong dipolar interaction. The observed decrease in SAR of the HT sample, despite its somewhat
larger anisotropy constant, is explained by taking into account the effects of magnetic dipolar
interactions using the so called T* model.
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CHAPTER 5 GADOLINIUM DOPED Fe3O4 NANOPARTICLES
FOR MAGNETIC HYPERTHERMIA
5.1: Introduction
Integration of diagnostic imaging and therapeutic function into a single platform, socalled “Theranostics”, is of great research interest as a new direction in nanomedicine research
[1]. Theranostics refer to agents that allow the combined diagnosis, treatment and follow up of a
disease, and are expected to contribute to personalized medicine. Superparamagnetic Fe3O4 is
considered as an ideal vehicle in the development of theranostic nanomedicines as they can be
multi-purposely used for magnetic resonance imaging (MRI) and targeted delivery of therapeutic
agents such as anticancer drugs, siRNA and magnetic hyperthermia (MHT). Several different
approaches of developing Fe3O4-based theranostic agent for multimodal and multifunctional
applications are shown in the figure 5.1.

Figure 5.1: Different approaches adopted in developing a SPION-based theranostic agent [141].
The application of superparamagnetic Fe3O4 in magnetic hyperthermia is well described
in the earlier chapters. Another attractive application of superparamagnetic nanoparticles is to be
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used as next generation of imaging probes in Magnetic resonance imaging (MRI). MRI is one of
the most powerful and noninvasive medical diagnostic tools by monitoring the change in
magnetization of hydrogen-protons in water molecules contained in a tissue, when placed in a
magnetic field and exposed to a pulse of radio frequencies. This mapping provides a picture of
anatomical structure due to the fact that protons in different tissues with varying water
concentration and magnetic resonance properties react differently.
Contrast agents are used to enhance the images as they affect the behavior of the protons
in their vicinity sharpening the contrast. Contrast agents used in MRI are divided into two
categories; T1 and T2 contrast agents based on their effect on the magnetic relaxation processes of
the protons [142]. The reduction in the T1relaxation time (higher rate 1/T1), enhances the signal
resulting a brighter image whereas the reduction in T2 relaxation time (higher relaxation rate,
1/T2) decreases the signal, darkening the image. Most commonly used T1 contrast agents are
paramagnetic compounds that are composed of metal ion with permanent magnetic moment due
to unpaired electrons [gadolinium (Gd3+) or manganese (Mn2+)] and a chelating ligand, such as
diethylene triamine pentaacetic acid, DTPA [142,143]. The chelate prevents the lanthanide from
binding to chelates in the body making the paramagnetic lanthanide ion less toxic. T1 contrast
agents mainly reduce the longitudinal (T1) relaxation which is due to energy exchange between
the spins and surrounding lattice (spin-lattice relaxation) and result in a brighter signal. The
second class, T2contract agents, consists of superparamagnetic nanoparticles, such as Fe3O4,
have a strong effect on the transversal (T2) relaxation properties. In an external magnetic field,
nanoparticles are magnetized and generate induced magnetic fields locally. These induced fields
perturb the magnetic relaxation processes of the protons in the water molecules, especially the
spin-spin relaxation (transverse relaxation). The transversal (T2) relaxation time decreases which
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results in darkening of MR images. The role of superparamagnetic nanoparticles as T2 contrast
agent explained above is depicted in figure 5.2.

Figure 5.2: Magnetic nanoparticles as T2contrast agent for MRI. [144]
When using nanoparticles as contrast agents for MRI, it is crucial that they are captured
into the cells efficiently upon the exposure.

There are various research studies done on

enhancing the MRI signal for cancer detection using superparamagnetic Fe3O4nanoparticles as
T2 contrast agents [145-147]. For example, Jun et al. [148] have successfully synthesized
superparamagnetic iron oxide nanoparticles of 9 nm size as magnetic probes for the in-vivo
detection of cancer cells implanted in a mouse. In their research work, 2, 3-dimercaptosuccinic
acid (DMSA) ligand is attached to the nanoparticles surface to obtain hydrophilic nanoparticles
and the nanoparticles are further conjugated with the cancer-targeting antibody, Herceptin. The
specific binding properties of Herceptin against a HER2/neu receptor over-expressed from breast
cancer cells lead to the successfully detection of breast cancer cells (SK-BR-3) hence gives a
dark MR image.
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Even though both T1 and T2 mapping are powerful techniques, single mode contrast
agents are not always sufficient in modern diagnosis as they have certain drawbacks and
limitations [149]. For example, the dark contrast produced by T2 agents can also be generated
from adjacent bones or vasculatures or there can be susceptibility artifacts due to the sharp
change in magnetic field surrounding the contrast agent. Also, Gd-chelates (T1 agent) have high
mobility which shorten their presence in the vascular system and raise possible toxicity issues.
Thus, there is a growing interest in developing complementary T1–T2 dual-modal contrast agents,
combining the advantages of positive and negative contrasts to obtain high sensitivity and
biocompatibility for improved diagnosis [150]. Two different approaches of integrating T1 and
T2species have been reported recently [149]. One is constructed by labeling T1 signaling
elements (Gd species) on magnetic nanoparticles. In the study done by Bae et al [151],GdDTPA,a representative Gd chelate-based T1 MRI contrast agent, is covalently attached to
dopamine-coated iron oxide nanoparticles. Their results demonstrated that the composite not
only had the ability to improve surrounding water proton signals on the T1-weighted image, but
also could induce significant signal reduction on the T2-weighted image. In another study
reported by Santra et al. [152], Gd-DTPA is encapsulated within the poly (acrylic acid) (PAA)
polymer coated superparamagnetic iron oxide nanoparticle (IO-PAA) conjugated to folic acid
which act as the targeting ligand for breast cancer cells (HeLa cells). When nanoparobes
internalized within the cells, which is acidic, composite magnetic nanoprobe degraded resulting
in an intracellular release of Gd-DTPA complex with subsequent T1 activation which can be seen
by MRI. Authors claim that thisT1 nano-agent could be used for the detection of acidic tumors.
The other type of conjugated system consists of T1 paramagnetic elements embedded into T2
magnetic nanoparticles. For example, Zhou et al [153] have synthesized Gd2O3-embedded iron
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oxide nanoparticles with an overall size of 14 nm which can act as a T1 –T2 mutually enhanced
dual-modal contrast agent for MR imaging of liver and hepatic tumor detection with great
accuracy in mice. Xiao et al [154], have prepared PEGylated, Gd-doped iron oxide nanoparticles
which is applicable as a T1–T2 dual-modal MRI contrast agent. Their in-vivo MRI results
demonstrated the simultaneous contrast enhancements in T1- and T2-weighted MR images
towards the glioma bearing mice.
Even though the multi-functionality of superparamagnetic Fe3O4 nanoparticles based
nano systems for drug delivery and imaging modalities [141] has been investigated widely, the
possibility of incorporating magnetic hyperthermia and MRI is not explored much. In addition to
be used as a T1 –T2 dual-modal contrast agent for MR imaging, Gd doped Fe3O4nanoparticles
has the potential to act as an effective MHT agent [155]. Gd (III) is known to oppose net
magnetic moment of Fe (III)/Fe (II) in oxides, reducing magnetizations [156-158]. Therefore Gd
doping may reduce the hyperthermia efficiency but by using the correct amount of doping we
can always explore the possibility of using them as both MRI contrast agents and hyperthermia
mediators. To the best of our knowledge, there are very few studies done on the magnetic
hyperthermia efficiency of Gd doped Fe3O4nanoparticles [159,160]. Both the studies report
higher SAR values for Gd doped (< 1%) Fe3O4nanoparticles compared to the reported values for
undoped samples.
In this study, we synthesized Gd–Fe3O4 (2.5 at %) using co-precipitation technique,
followed by the structural and magnetic characterizations. We found that the doping of Gd3+ ions
into Fe3O4 spinel has significantly influenced the average crystallite size and the saturation
magnetization. We conducted the magnetic hyperthermia experiments on the Gd doped Fe3O4and
our detailed analysis demonstrate that the SAR value of the doped samples is similar to the
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undoped Fe3O4despite the reduction of the magnetization upon doping. This study raises the
possibility of using Gd–Fe3O4nanoparticles for multimodal contrast imaging and cancer
treatment by hyperthermia.
5.2: Synthesis and Structural Characterization
Gd doped Fe3O4 nanoparticles were synthesized by a co-precipitation method, and coated
with dextran according to the details explained in chapter 3. For a typical synthesis of 2.5 at%
Gd–Fe3O4, aqueous solution of FeCl2.4H2O, FeCl3.6H2O and Gd(NO3)3were prepared in a molar
ratio of 1.00 : 1.925 : 0.075 in 25 ml volume followed by the addition of 250 ml of 1M NH4OH.
The concentration of the produced ferrofluid was adjusted to 12 mg/ml for further measurements.
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Figure 5.3 shows the XRD pattern of both the Gd doped and undoped Fe3O4 nanoparticles.
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Figure 5.3: XRD spectra for (a) Fe3O4 nanoparticles (b) Gd-doped Fe3O4 nanoparticles
All the observed peaks in the XRD patterns can be indexed to the Fe3O4 crystal structure
with no evidences for the presence of other crystalline impurity phases in significant amounts.
According to the earlier studies Gd3+ ions tends to replace the Fe3+ ions of the octahedral sites in
inverse spinel crystal structure [161]. From the XRD spectra, it is observed that Gd doping does
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not disturb the Fe3O4crystal structure significantly. Using several intense XRD peak and the
Debye-Scherer equation the crystallite sizes of the Fe3O4and Gd doped Fe3O4nanoparticles
samples were determined to be 11.7±0.6 nm and 14.9±0.5 nm respectively. This increase in the
crystalline size is consistent with the previous studies done on Gd doping on spinel structures
[162]. TEM images of the two samples are shown in the Fig. 5.4. The undoped sample consists
of roughly spherical nanoparticles with smaller polydispersitywhereas the Gd doped sample
exhibits nanoparticles with rough edges with wider size distribution.

Figure 5.4: TEM images of (a) Fe3O4 and (b) Gd doped Fe3O4 nanoparticles
5.3: Magnetic Characterization
The M-H data for undoped and Gd-doped Fe3O4 ferrofluid samples, recorded at room
temperature, are shown in Fig. 5.5. The sigmoidal shape of the M (H) curves with nearly zero
hysteresis confirms the superparamagnetic nature of these nanoparticles at room temperature.
The saturation magnetization of Fe3O4 nanoparticles is measured to be ~ 72 emu/g whereas that
of Gd-doped Fe3O4 nanoparticles is reduced ~ 52emu/g. This reduction in saturation
magnetization at room temperature agrees with the observations in other reported studies
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[154,162] and can be attributed to the fact that magnetic Fe3+ ions are supposedly getting
replaced by the Gd3+ ions in the octahedral sites of the inverse spinel structure.

Figure 5.5: M vs H curves for two ferrofluid samples fitted with the particle size distribution
incorporated langevin function. The inset shows the resulting particle size distribution of the two
samples.
The black lines show the theoretical fit using a Langevin function for the magnetization as a
function of H incorporating the particle size distribution and dipolar interactions using Eq. 2.11. The

inset shows the magnetic core size distributions for two ferrofluid samples. The fitting
parameters for the two samples are shown in Table 5.1.
Table 5.1: Fitting parameters obtained from the M (H) fitting with modified Langevin
function
Ferrofluid Sample

Ms(emu/g)

D0 (nm)

λ

T* (K)

Davg (nm)

Fe3O4

72

11.6

0.15

80

11.7±1.9

Gd -Fe3O4

52

14.2

0.23

100

14.6±3.7

62
According to the fitting parameters, Gd-doped Fe3O4 nanoparticles have a higher average
magnetic core size with a larger size distribution (14.6±3.7 nm) compared to the undoped Fe3O4
nanoparticles (11.7±1.9 nm). Both the ferrofluid samples exhibit similar strength of magnetic
dipolar interaction (T* ~ 80-100 K).
5.4: Magnetic hyperthermia characterization
MHT measurements were carried out on the dextran coated Gd-doped and undoped
Fe3O4ferrofluid samples at a field of 235 Oe and at a frequency of 375 kHz. The heating curves
for two samples are shown in Fig. 5.6 (a) and from the plot it can be observed that the initial
rates of heating for the two samples are roughly the same. From these heating curves the SAR
values were obtained as a function of temperature taking into account of heat loss as described in
the previous chapter.

Figure 5.6: (a) Heating curves (Temperature vs time) for Fe3O4 and Gd-doped Fe3O4 ferrofluid
samples under an ac magnetic field amplitude of 235 Oe and at a frequency 375 kHz. (b) The
temperature dependence of net SAR for two ferrofluid samples. The black line shows the
theoretical fitting of the experimental data with the linear response theory.
Figure 5.6 (b) presents the corrected experimental SAR data (symbols) as a function of
temperature for both the undoped and Gd doped samples. Within the experimental error, the
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room temperature SAR values for Gd-doped Fe3O4and undoped Fe3O4 ferrofluid are very similar.
The temperature dependent SAR values were fitted to the linear response theory incorporated with
the interactions and size distribution using the expression given in Chapter 2 (Eq. 2.23). The solid

lines in Fig. 5(b) are the best fits to the experimental SAR data, using the particle size
distribution parameters and T* values given in Table 5.1and treating the anisotropy constant,
K, as a fitting parameter. The SAR fitting yields a somewhat smaller anisotropy constant (~ 12
kJ/m3) for Gd-doped ferrofluid compared to that of undoped ferrofluid (~ 21kJ/m3).
Figure 5.7 shows SAR as a function of the magnetic core size (D0) in an AC magnetic
field of 235 Oe and a frequency of 375 kHz at 298 K using the fitted values of Ms, D0, and λ
obtained from our analysis of M-H (Table 5.1) and K values from MHT fitting of undoped
Fe3O4and Gd-doped Fe3O4 ferrofluidsamples.

Figure 5.7: Simulated SAR as a function of particle size. The symbols correspond to the
experimental data. The parameters used are T = 298 K, H = 235 Oe, f = 375 kHz and
values listed Table 5.1.
For the simulation of SAR we used Eq. 4.3 that contains the dipolar interaction
modification. The symbols correspond to the experimental SAR obtained for our two ferrofluid
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samples. As explained in the previous chapter, SAR increases with D0 until it reaches a
maximum value at a critical size and decreases with further increase in D0. The larger size
distributions broaden the peak reducing the maximum SAR at the critical size. For both of our
undoped and Gd-doped Fe3O4 samples, the particle size is below this critical size. It is seen here
that, the critical sizes at which SAR is maximum shift to a lower value as K increases. Hence by
reducing the amount of Gd doping amount it may be possible to obtain a Gd-doped Fe3O4 sample
with a magnetic core size in between 12-14nm, magnetization and K higher than the values
obtained for this Gd-doped Fe3O4 sample which will result in a higher SAR than the observed
values.
5.5: Conclusions
Gd- doped iron oxide nanoparticles have been synthesized using the simple and widely
used co-precipitation method and coated with dextran. The aim of the study was to understand
the effect of the Gadolinium doping on the magnetic properties of nanoparticles and the
associated magnetic hyperthermia response of the ferrofluids. Hence, the undoped iron oxide
nanoparticles synthesized under the same experimental conditions were used as the control. The
magnetization data reveals that the saturation magnetization decreases upon Gd doping. M vs H
data were fitted with the langevin model incorporated with the log normal size distribution as
well as dipolar interactions. Comparing the crystalline sizes (XRD) and magnetic core size
distributions obtained from the langevin fitting of two samples, it is observed that Gd doping
increases the magnetic core size and causes an increase in the polydispersity of the nanoparticles.
Moreover, magnetic hyperthermia measurements were performed on dextran coated ferrofluids
and the experimental SAR values (corrected for heat loss) were fitted using the linear response
theory. It is evident from the analysis that the magnetocrystalline anisotropy (K) is decreased by
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several units upon Gd doping. The reduction in the saturation magnetization and K would
generally result in a decrease in SAR but here the increased particle size distribution
compensates the negative effect on SAR. Therefore, the obtained SAR value of the Gd doped
Fe3O4 nanoparticles is similar to that of undoped Fe3O4 ferrofluid. Both the samples exhibits the
same strength of interactions according to our analysis hence does not exhibit a significant
impact on SAR. To conclude, the Gd doping on the Fe3O4 nanoparticles affect the morphology
and the magnetic properties of Fe3O4 nanoparticles considerably but the magnetic hyperthermia
efficiency of the samples were about the same within the error limits. By fine tuning the
composition of Gd doped Fe3O4 nanoparticles, we may achieve a higher SAR value. The
possibility of using Gd doped Fe3O4 nanoparticles as a dual modal T1-T2 contrast agent is being
currently explored by others and our magnetic hyperthermia results demonstrate that this
material is a potential candidate for theronostics for multimodal contrast imaging and cancer
treatment by hyperthermia.
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CHAPTER 6 A COMPARATIVE STUDY OF MAGNETIC
HYPERTHERMIA AND CYTOTOXITY OF DEXTRAN AND
CITRIC ACID COATED Fe3O4 NANOPARTICLES
6.1: Introduction
In the design of magnetic nanoparticles for biomedical applications, surface coating plays
an important role as it fulfills more than one function at a time. In general, the surface coating is
important for three main reasons:

First, it provides the colloidal stability of ferrofluids

preventing the particle clustering (reducing particle interactions). Second, the coating provides
the biocompatibility which is a crucial factor in clinical applications. It ensures a double-sided
isolation, preventing any toxic ion leakage from magnetic core into the biological environment as
well as shielding the magnetic core from oxidization and corrosion. Third, it serves as a base for
conjugating various functional groups such as targeting ligands, therapeutic drugs according to
desired application. All these aspects were described in details in Chapter 2. In addition to that,
surface coating can endow the nano system with long circulation properties making them
“stealth” systems. When nanoparticles are injected into the body during in vivo applications,
they are often recognized by reticuloendothelial system (RES) that eliminates any foreign
substance from blood stream [163]. In this process, nanoparticles are rapidly attacked by the
plasma proteins from RES and shuttled out of circulation to the liver, spleen or kidney which
then cleared out from the body. Also this RES accumulation often causes toxicity issues as well.
The specific surface coatings can prevent the adsorption of these proteins, increasing the
circulation time in blood hence maximize the possibility to reach target tissues [164]. For
instance, it is well known that coating of hydrophilic polymers, mainly poly (ethylene glycol)
(PEG), on the nanoparticles reduces nonspecific binding of the proteins resulting in stealth
behavior.
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The effect of the surface coating on magnetic properties and hence on the efficiency of
the desired application is still not well understood. Therefore, fine tuning of surface coating
materials is a major challenge in current research on the clinical applications of magnetic
nanoparticles. During the surface coating on the nanoparticles, coatings molecules interact with
the surface atoms of the magnetic core and may form a magnetically disordered layer. This can
reduce the total amount of the magnetic phase. Different coatings exhibits different interactions
with the magnetic core and therefore produce unique effective nonmagnetic layer thicknesses.
However the discrimination between surface coating and finite size contribution is a difficult
task especially in the smaller particles where the latter effect is dominant since the volume
fraction of disordered surface spins are increased. There are many literature found on different
surface coatings on different kind of magnetic cores and the surfactants effect on the magnetic
properties [165-169]. In a study reported by Yuan et al. [168], effect of surfactant on magnetic
properties was investigated using commercially available aqueous nanoparticle suspensions,
FluidMAG-Amine, FluidMAG-UC/A, and FluidMAG-CMX, in parallel with oleic acid covered
particles suspended in hexane and heptane. Their results reveal the reduction of magnetic phase
in nanoparticles which varies with different coatings as well as with solvents. The magnetic
reduction in different coatings was attributed to the different degree of surface spin disorder due
to the absorbance of coatings and electric charge whereas the solvent dependent magnetic
reduction was attributed to the difference in coating and the magnetic core interaction strengths
in different solvents.
The saturation magnetization is a main factor that determines the magnetic hyperthermia
efficiency hence the change on the magnetic properties from the surfactant should influence SAR
as well. Therefore a useful approach to improve the magnetic hyperthermia performance is to
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optimize the surface coating to maximize the SAR. As for now there are conflicting SAR values
obtained for a certain sized nanoparticle makes it difficult to evaluate the exact contributions of
surface coating on the SAR. The study done by Liu et al [170], reports the possibility of
increasing SAR by decreasing the surface coating thickness using highly monodispersed Fe3O4
nanoparticles with different mPEG coating thickness. According to his explanation, a decrease in
coating thickness lead to an increased Brownian loss, improved thermal conductivity as well as
improved dispersibility resulting in increased in SAR. The optimized sample is further tested for
magnetic hyperthermia in simulated physiological environments with protein (bovine serum
albumin, BSA), blood sugar (dextrose), electrolytes (saline) and phosphate buffered saline
(PBS). In another study reported by the same authors, superparamagnetic Fe3O4 nanoparticles
after coating of Human-like collagen (HLC) show effective heat conduction under an AC
magnetic field compared to uncoated sample despite of the slight reduction in saturation
magnetization upon coating. According to Mohammad et al it is also found that inorganic
coatings improve the SAR value [171]. They found that gold coating retains the
superparamagnetic fraction of the superparamagnetic Fe3O4 nanoparticles much better than
uncoated nanoparticles alone and leads to higher magnetocrystalline anisotropy. In another study
done by Filippousi et al. [165], authors use three diverse (different molecule length, polar head
group and charge) and widely used surfactants, cationic cetyltrimethylammonium bromide
(CTAB) surfactant, the nonionic polyvinylpyrrolidone, K30 (PVP) surfactant, and the anionic
sodium cholate (S.C.) surfactant to investigate their possible influence on the magnetic properties
and the heating response. Their results show that CTAB coated sample yields a lower
magnetization (29.8 Am2 /kg) compared to the rest of the samples (~ 50 Am2 /kg) due to its more
prominent oxidation and shows the lowest SAR among all samples.
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In our study presented in this chapter, we investigated the effect of surface coating on
temperature dependent SAR using two biocompatible surfactants dextran and citric acid (CA).
To compare the effect of coating, we used the same batch of Fe3O4nanoparticles for coating
(post-synthesis coating) and studied the structural and magnetic properties as well as the
colloidal stability of the dispersions. We also examined the influence of surface coating by
systematically investigating the SAR of ferrofluids in slightly basic water solution as well as in
simulated physiological environments with protein (bovine serum albumin, BSA).
6.2: Characterization of dextran and citric acid coated Fe3O4 ferrofluids
The Fe3O4 magnetic nanoparticles were synthesized using the chemical co-precipitation
route, as described in Section 3.1.1. The synthesized nanoparticles were then coated with dextran and
CA based on the procedure outlined in Section 3.2.1 and Section 3.2.2.The concentrations of both the
ferrofluids were adjusted to 12 mg/mL. The schematic diagram of the surface coated nanoparticles is
shown in the figure 6.1.

Figure 6.1: Schematic representation of dextran coated and citrate capped Fe3O4
magnetic nanoparticle
The phase purity Fe3O4 crystalline structure of the as-synthesized nanoparticles was
confirmed by the x-ray diffraction and the crystalline size was estimated to be 11.7±0.6 nm from

Debye-Scherer analysis (XRD pattern not shown). The morphology of these nanoparticles was
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investigated and the particle size distribution was also determined to be 13.2±2.3 nm using TEM
as shown in figure 6.2. These obtained values are very similar to that of previous samples
prepared for our earlier studies which confirm the reproducibility of the synthesis method.

Figure 6.2: TEM images of as prepared Fe3O4and nanoparticles with the particle sizes fitted to
log normal distribution.
The colloidal properties, zeta potential (ξ) and hydrodynamic size (D H), of the two
ferrofluids were characterized using DLS measurements. The hydrodynamic size of dextran
coated and CA coated Fe3O4 ferrofluids in aqueous media at pH of 7.4 were estimated to be 100
±25 nm and 30 ± 5 nm respectively. The pH dependent ξ values were measured as shown in the
figure 6.3. Both the ferrofluids show negative surface charges indicating their stability over a
wide range of pH and the ξ values at pH 7.4 are estimated to be around -17 mV for dextran
coated Fe3O4 and -27 Mv for CA coated Fe3O4.The large/small value of ξ indicates a more/less
electrostatic repulsion between the nanoparticles which opposes the magnetic attraction acting
between the nanoparticles. Therefore, our data indicates that, CA provides a higher stability
compared to the dextran coating for the whole range of pH.
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Figure 6.3.pH dependent zeta potentials of different surfactant coated Fe3O4
nanoparticles
6.3: Effect of surfactant coating on magnetic properties of Fe3O4 ferrofluids
The M (H) curves for both the dextran and CA coated Fe3O4 ferrofluids were obtained at
300 K as shown in the figure 6.4. The saturation magnetization of both the ferrofluid samples
was similar to the value obtained for uncoated Fe3O4 (~ 72 emu/g, reported in Chapter 5)
indicating that the surface coating did not affect the magnetization of the sample. However, the
magnetic core size of the CA coated ferrofluid obtained from the interaction incorporated
Langevin function fitting analysis is slightly lower with a larger size distribution compared to the
values obtained for the dextran coated ferrofluid as listed in Table 6.1. Even though we used the
same nanoparticles for coating, due to the different reaction conditions and the different coating
materials used, the surface of the nanoparticles are modified differently. The interactions
parameter, T*, obtained for dextran and CA ferrofluids are in the range of 60-80K which
indicates that both the coating provide excellent stabilityand reduce the inter-particle interactions
producing a ferrofluid closer to ideal system.
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Figure 6.4: M vs H curves for two ferrofluid samples fitted with the modified Langevin
function. The inset shows the resulting particle size distribution of the two samples. (red line
represents CA coated sample, blue line represents Dextran coated sample)
Table 6.1: Fitting parameters for Dextran and CA coated Fe3O4 ferrofluid samples.
M-H curve fitting
Ferrofluid Sample

Ms
(emu/g)

D0 (nm)



T* (K)

Davg(nm)

Dextran-Fe3O4

74

11.6

0.15

80

11.7±1.8

CA _Fe3O4

72

11.2

0.21

60

11.5±2.4

6.4: Magnetic hyperthermia of dextran and citric acid coated Fe3O4 ferrofluids
The magnetic hyperthermia measurements were made on ferrofluids samples, with 12
mg/ml concentration, using an ac magnetic field of amplitude of 235 Oe and frequency of 375
kHz in the temperature range of 25 - 50 oC, as described in earlier chapters. The heating curves
and the corresponding plots of SAR as a function of temperature shown in Fig. 6.5 for both
dextan and CA coated samples. The initial SAR values of the samples are very similar (105-110
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W/g) within the experimental error limits, and it decreases with the increase of temperature.
Dextran coated ferrofluid shows a higher decrease in SAR with temperature whereas this
decrease is smaller in CA coated ferrofluid. This difference may due to the different size
distributions as well as the thermal properties of the two ferrofluids. Using the parameters listed
in Table 6.1, we fitted the temperature dependent SAR curves using modified linear response
theory to obtain the values of K as a fitting parameter. Interestingly, both the samples yield very
similar values 21-22 KJ/m3.

Figure 6.5: Left:Temperature vs time curves for dextran and CA coated Fe3O4 ferrofluid samples
of 12mg/ml concentration at a frequency 375 kHz and under acmagnetic field amplitude of 235
Oe. Right: The temperature dependence of net SAR for two ferrofluid samples. The black line
shows the theoretical fitting of the experimental data with the linear response theory.
6.4.1: Effect of Concentration on the magnetic hyperthermia efficiency
In order to understand the stability of the ferrofluids upon dilution and its effect on the
magnetic hyperthermia efficiency, we conducted a series of experiments to measure the SAR at
different concentrations. From the stock concentration of 25 mg/ml, we prepared dilute
ferrofluids with concentration of 12mg/ml, 6 mg/ml and 3 mg/ml, using DI water as the solvent.
The SAR values obtained for different concentrations of two ferrofluid samples at room
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temperature are shown in the Fig. 6.6 (filled symbols). A decrease in SAR was observed upon
dilution for both ferrofluids. In general, it has been observed that a decrease in concentration
would result in an increase in the inter-particles distance, decreasing the dipolar interactions
between particles which in turn results in an increase in SAR [172-174]. However the
contradictory results obtained from our data may be due to the poor quality of the diluted
samples containing clusters/aggregates formed upon dilution. Therefore, when diluting the
samples, more precautions might be taken or we could try to dilute with a week base solution.

Figure 6.6: SAR values of dextran and CA coated Fe3O4 samples at different
concentrations at 25 °C. All the data was obtained at a frequency of 375 kHz and ac
magnetic field amplitude of 235 Oe.
6.4.2: Effect of the solvent media on the hyperthermia efficiency
Whenever nanoparticles encounter biological systems, interactions take place between
their surfaces and biological components such proteins, membranes, phospholipids, DNA
forming so called “protein corona” around the nanoparticles [175,176]. Upon the exposure, faster
binder interacts with the nanoparticle surface forming the initial corona, however they eventually
are replaced by proteins with the highest affinity to the surface (Vroman effect) [177]. The initial
corona formed on short time scales (seconds to minutes) is called “soft” corona whereas the one
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that forms in later times over period of hours is called “hard” corona. The adsorption of serum
proteins on the nanoparticles surfaces in a biological system has been widely studied, often
focusing on the effect on cell uptake and cytotoxicity of the particles [178-181]. The formation
of corona depends on the surface properties of the particles [182,183] and can influence the
aggregation behavior of nanoparticles in biological media, which in turn can affect their
performance for desired applications. Therefore, apart from the optimization of the properties of
the magnetic core and surface coating for high performance magnetic hyperthermia, it is
necessary to ensure its performance in the physiological environments. In the work reported by
Khandhar et al [184], authors use poly(maleic anhydride-alt-1-octadecene)-poly(ethylene glycol)
(PMAO-PEG), an amphiphilic polymer coated Fe3O4nanoparticles of three different sizes, 13
nm, 14nm and 16 nm, to study the magnetic hyperthermia efficiency in cell growth medium
(CGM) similar to biological environment. Their results show an increase in hydrodynamic sizes
in all three samples upon exposure to CGM. SAR is reduced (30%) only in 16 nm size sample
while other two samples did not exhibit any significant decrease in SAR. Authors suggest that
the increase in hydrodynamic volume prolongs Brownian relaxation while Neel relaxation is
unaffected. Hence in 13 and 14 nm samples where SAR is mainly due to Neel relaxation, SAR
was not affected. But in 16 nm samples, in which there is a contribution from Brownian
relaxation to heat dissipation, the SAR dropped due to the increase in Brownian relaxation.
We investigated the magnetic hyperthermia efficiency of dextran and CA coated Fe3O4i
ferrofluids in cell growth medium which contains serum proteins similar to physiological
environments. From the stock solutions (25 mg/ml), 3mg/ml concentration of dextran and CA
coated ferrofluids samples were prepared using cell growth medium (CGM) and DI water. The
ferrofluid samples were subjected to an alternating magnetic field of amplitude, 235 Oe and the
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frequency of 375 kHz and the time dependent temperature was measured followed by the
analysis described in the earlier chapter. The SAR of dextran coated samples in DI and CGM
were estimated to be 63 W/g and 72 W/g respectively which indicate that their performance is
not much affected by the medium if not enhanced. However, SAR values obtained for CA coated
samples in DI and CGM, 78 W/g and 38 W/g, implies that their efficiency is heavily reduced
when exposed to physiological environments. The summary of the results of solvent dependent
SAR is shown in figure 6.6.
In order to explore the reason for this reduction of hyperthermia efficiency in CGM, we
measured the hydrodynamic sizes of dextran and CA coated ferrofluids samples at different
incubation times from few minutes to 24 hours upon exposure to CGM. As seen from the
measured values, the hydrodynamic sizes of both the ferrofluids are increased, each at different
rates (see Fig 6.7). The increase in the sizes can be attributed to the formation of protein corona
upon the nanoparticle exposure to the serum proteins in CGM. Dextran and CA coating endow
the nanoparticles surface with different surface chemistries. For example CA coating provides
the more active carboxyl functional groups making the surface hydrophilic andincreasing the
electrostatic repulsion between the particles. On the other hand, dextran coating has hydroxyl
groups, and interactions between the particles are reduced mainly due to steric repulsion than
electrostatic repulsion. When CA coated Fe3O4 is exposed to serum proteins, the proteins rapidly
bind to their surface forming a protein corona. As a result its hydrodynamic size increases
quickly and reaches to the maximum value within 5 hours. This in turn reduces the stability of
the ferrofluid, leading the particles to form aggregates reducing the SAR value.
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Figure 6.7: Hydrodynamic sizes of dextran and CA coated Fe3O4 samples at different
times at 25 °C. Red symbols represent CA coated sample, blue symbols represent
Dextran coated sample. Closed symbols are for ferrofluids diluted using CGM and open
symbols are for ferrofluids diluted with DI.
Compared to CA coated particles, dextran coated nanoparticles show much stability at
least during first 3 hours upon exposure to the serum proteins. The formation of the corona takes
place at a slower rate which may due to the steric hindrance and the low activity of hydroxyl
groups. Therefore its hyperthermia efficiency is not reduced as in CA coated Fe3O4 sample. A
schematic representation of the protein corona formation is shown in Fig. 6.8. However, when
analyzing the data obtained from hydrodynamic size measurements, it should also be noted that
not only the protein corona but also free-protein clusters are likely to influence the results.
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Figure 6.8: Sketched evolution of the nanoparticle agglomeration process when in
contact with protein-rich medium such as DMEM + FBS
6.5: Cytotoxicity studies on human pancreatic cancer cells
As mentioned earlier, one of the basic and an important requirement that should be
fulfilled by nanoparticles for them to be used for biomedical applications is the non-toxicity. We
tested the cytotoxicity of dextran and CA coated Fe3O4 ferrofluids by performing trypan blue
exclusion technique [185], an established cytotoxicity protocol, followed by cell counting using
hemocytometer [186] on human pancreatic cancer cells, Mia PaCa 2. Same amount of MIA
PaCa-2 cells were seeded in 100 mm dishes containing 10 ml of cell growth medium (10% fetal
bovine serum,5% penicillin in Dulbecco’s modified essential medium),and were incubated for 24
hours at 37 °C in a humidified 5% CO2 atmosphere in order to make cells attached to the bottom
of the culture plate. Then half of the medium was replaced with the fresh medium containing
dextran and CA coated Fe3O4 ferrofluids of 200 µg/mL concertation which makes the final
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concentration 100µg/mL in each dish. Fresh cell growth medium without nanoparticles were
used for the control experiments. After incubating the cells with the nanoparticles coated with
dextran and CA for 24 and 48 hours, the supernatant was taken out and stored in a corning flask.
This supernatant contains any dead cells that are detached from the cell bottom. Then 2 ml
trypsin was added, incubated for 3 minutes in the incubator followed by the addition of the cell
growth medium. This cell solution was mixed with the corresponding supernatant that was stored
previously. Now the cells were centrifuged at 1500 rpm for 3 minutes, supernatant was removed
and the cell pellet was dissolved in 2ml of cell growth medium. Out of the concentrated cell
suspension, 100 µL was taken and mixed with 100 µL of 0.4% trypan blue solution. Then 10 µL
of the resultant solution was loaded on a hemacytometer and examined immediately under a
microscope at low magnification. The cells that are dead or non-viable will take up trypan blue,
result in blue color. The number of blue staining cells and the number of total cells were counted
to estimate the cell viability using the Eq. 6.1. The experiments were done in triplicates.

Number of blue cells

% viable cells = [1 − Number of total cells] × 100%

(6.1)

According to the results, both the cells that are exposed to dextran and CA coated Fe3O4
nanoparticles show the same viability as the normal cells that are not exposed to the
nanoparticles. This indicates that at the concentrations of 100 µg/mL or lower, nanoparticles
coated with dextran and CA do not show any toxic effect on the cells. The cytotoxicity results
are shown in the Figure 6.9.
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Figure 6.9: Cytotoxicity for dextran and CA coated Fe3O4 nanoparticles on Mia PaCa 2
cells as determined by counting live cells using Trypan Blue assay. Experiments were
conducted in triplicate with n = 3. Error bars represent the standard deviation.
6.6: Conclusions
In this study we investigated the effect of two coatings, dextran and CA, on the colloidal
and magnetic properties of Fe3O4nanoparticles as well as their impact on magnetic hyperthermia
efficiency. Both the ferrofluids (dextran and CA coated) show similar magnetic properties, with
same value of SAR in DI water. Our concentration dependent magnetic hyperthermia results
indicate that the dilution of the sample should be done with extensive care as it may promotes
cluster formation which in turn reduces the SAR value. Moreover, upon exposure to cell growth
medium that mimics the physiological environment, formation of corona was observed for both
dextran and CA coated nanoparticles as seen from the hydrodynamic size measurements. It was
observed that in CA coated particles where, this protein corona forms faster, in several minutes
to hours, that causes aggregations in solution which in turn reduce SAR by ~ 45%. But dextran
coated nanoparticles show a better stability at least within first 3-6 hours upon exposure to the
proteins in the cell growth medium exhibiting excellent performance in both water and simulated
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physiological conditions. The cytotoxicity studies done on human pancreatic cancer cells
indicate that both dextran and CA coated Fe3O4 ferrofluids are nontoxic to the cells at or below
100 µg/mL concentration. Though further in vivo study is necessary in the future, these results
imply that the dextran coated Fe3O4 dispersion could maintain their high heating capacity in
physiological environments while CA coating require further surface modification to reduce the
non-specific protein adsorption.

82

CHAPTER 7 TIME-DEPENDENT CELLULAR UPTAKE AND
DISTRIBUTION OF DEXTRAN-COATED IRON OXIDE
NANOPARTICLES
7.1: Introduction
Aa mentioned in the earlier chapters, superparamagnetic Fe3O4nanoparticles (SPIO) are
currently one of the most important and acceptable nanoparticles since they can be multi
purposely used such as for imaging, targeted drug delivery, magnetic hyperthermia, and cell
separation with external magnetic manipulation [49,187-189]. Fabricating a biocompatible, well
dispersed, stable colloidal dispersion of the nanoparticles with good magnetic properties is
crucial for clinical applications and intensive research continue to be carried out to further
improve the biocompatibility and dispersibility. Nanoparticles in the range of 10-200nm are
generally considered to be ideal for the biomedical applications since they are taken up by the
liver and spleen for clearance from the body. The cellular uptake, bio distribution, molecular
response and the potential toxicity of the SPIO nanoparticles are mostly based on the particles
size, physical shape, and surface chemistry [190]. Importantly, these cellular responses also
depend on the cell type [191].
Although, extensive studies have been carried out on the synthesis, biocompatibility,
surface modifications [190,192-195], cytotoxicity [196-198], and the in vivo targeting of
Fe3O4nanoparticles, a complete understanding of their interaction and subcellular distribution in
cells is yet to be fully realized. In present study, we have determined the traffic, distribution, and
the cytotoxic effects of the dextran coated Fe3O4 nanoparticles on Mia PaCa 2, human pancreatic
cancer cells. The mass spectroscopy was used as the tool to investigate the time dependent
distribution of the nanoparticles.
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7.2: Synthesis and characterization of Fe3O4 nanoparticles
Fe3O4 nanoparticles were synthesized by the co-precipitation technique as described in
section 3.1.1 with slight modifications. Here, the aqueous solution of Fe2+ / Fe3+ was kept under
constant magnetic stirring at 800rpm and 125 ml of 2M NH4OH solution was added drop wise
into the mixture. The nanoparticles were isolated with a magnet and washed several times with
deionized water until a neutral pH was reached. The portion of synthesized nanoparticles was air
dried and the resulting powder was used for the structural and magnetic characterization. The
XRD pattern for the bare Fe3O4 nanoparticles is shown in Fig 7.1.
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Figure 7.1: XRD pattern of synthesized 8 nm size Fe3O4 nanoparticles. Sample was
deposited on a glass substrate from acetone dispersion. Diffraction pattern was collected
on a Rigaku MiniFlex 600 X-ray diffractometer under CuKα radiation (λ = 1.5418 Å).
The peaks observed in this pattern were consistent with those of standard XRD pattern of
Fe3O4 reported previously (reference JCPDS No. 82-1533) which confirms crystalline nature of
the synthesized Fe3O4 nanoparticles with Face centered cubic structure. Also, the absence of any
unknown peaks confirms that there are no secondary phases formed and there is no significant
presence of crystalline impurities in the sample. The crystalline size of MNPs was estimated to
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be 7.2±0.8 nm by the use of Debye-Scherer’s equation. TEM images of the IONPs (Fig. 7.2)
reveal that the nanoparticles are spherical with a narrow particle size distribution. To determine
the particle size distribution, the sizes of the particles from multiple images were measured, and
the obtained sizes were sorted into a histogram, and the histogram data was fitted to a log-normal
distribution function as described in the earlier chapters. The histogram and the lognormal fits
are shown in the inset of Fig. 2. The average particle size and the standard deviation of the
distribution were estimated to be 7.7 nm and 1.7 nm respectively.
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Figure 7.2: TEM Image of bare Fe3O4 nanoparticles (A), size distribution plot with log normal
fitting (B).
M (H) curve shown in Fig. 7.3 demonstrate superparamagnetic behavior (no coercivity).
M (H) curve shown in Fig. 7.3 demonstrate superparamagnetic behavior (no coercivity).The
saturation magnetization of the Fe3O4 nanoparticles at 300 K was found to be 61 emu/g with a
maximum applied field of 10 kOe, which is lower than the reported values of bulk Fe3O4 (92
emu/g)[199]. The reduction in saturation magnetization may be attributed to the surface disorder
or spin canting at the particles surface [139].
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Figure 7.3: M (H) curve for 8 nm Fe3O4 nanoparticles at 300 K demonstrating the
superparamagnetic behavior with saturation magnetization of 61emu/g.
7.3: Conjugation of FITC to dextran-functionalized Fe3O4 nanoparticles
The synthesized nanoparticles were then coated with dextran to obtain the well suspended
ferrofluid and cross linked using epichhlrohydrin according to the detailed description presented
in Section 3.2.1 and 3.2.3 respectively. Conjugation of FITC to dextran-functionalized
nanoparticles was carried out using an established published procedure[200] , details of which is
presented in Section 3.2.4.
7.4: MIA PaCa-2 cellular studies
To investigate the interaction between cells and the synthesized Dex-Fe3O4-FITC
nanoparticles, MIA PaCa-2 cells were exposed to them and the cellular uptake, distribution, and
cytotoxicity were evaluated as described here. MIA PaCa-2 human pancreatic cancer cells were
grown on poly L-lysine-coated petri dishes in Dulbecco’s modified essential medium (DMEM)
containing 10% fetal bovine serum (FBS) and 5% Penicillin-Streptomycin. Approximately, 5 ×
104 MIA PaCa-2 cells were seeded in 35 mm dishes containing 2 ml of DMEM-10% FBS-5%
Penicillin-Streptomycin, were incubated for 24 hours at 37°C in a humidified 5% CO2
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atmosphere. After 24 hours, half the medium was removed, and replaced with fresh medium
containing FITC labeled Dextran coated SPIO nanoparticles so that the final concentrations are
0, 5 µg/ml, 50 µg/ml, 125 µg/ml. Cells were imaged using an Olympus FSx100 fluorescence
microscope in the green channel (excitation at 485 nm, emission at 530 nm). Fluorescence
images of the cells were taken at different time intervals: 0 hour, 6 hours, 24 hours and 48 hours.
After 48 hours, cells were washed three times with PBS solution to get rid of unbound
nanoparticles, trypsinized, centrifuged, and 5 × 104 of cells were cultured in new 35 mm dishes.
These cells, in which nanoparticles are internalized, were incubated at 37 °C in a humidified 5%
CO2 atmosphere for another 3 days. After 3 days, the old medium was replaced with fresh
medium, followed by imaging. Experiments were performed in triplicates.
The fluorescence images taken at different time intervals such as at 0h, 24hour, 48 hours
are shown in Fig. 7.4, and the increase in the fluorescent signals over time demonstrates
increased accumulation of the FITC functionalized SPIO in cells. According to the images, the
SPIO nanoparticles were internalized within cells during 48 hours of incubation at 37°C. The
SPIO nanoparticles were shown to exhibit dose dependent cytotoxicity and shown to be safe up
to the concentration level of 100 µg/ml on human cells [201]. Interestingly, even after 3 days of
incubation (Fig. 7.5), nanoparticles were still present in the cells. The presence of the
nanoparticles within the cells clearly indicates the inheritance of the nanoparticles from the
parent cells during cell division. Also at this time point, the cells incubated with 125 µg/ml of
SPIO show a significant decrease of cell number, which may be due to the inhibition of cell
division caused by the prolonged accumulation of nanoparticles.
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Figure 7.4: Images demonstrating the time-dependent binding and accumulation of FITC
functionalized dextran coated SPIO nanoparticles with cultured MIAPaCa2 cells. Top to Bottom:
0h, 24h, and 48h. Phase images of cells (a), (c), (e), Left to right: corresponding fluorescent
images. (b), (d), (f).

Figure 7.5: Phase image (a), fluorescent image (b), of cells showing the presence of FITC
conjugated dextran coated SPIO nanoparticles within the cells after 3 days of accumulation
indicating the inheritance of nanoparticles from parent cells to daughter cells during cell division.
Overlaid image of phase and fluorescent images (c) demonstrate that most of the nanoparticles
are at the membrane (white arrow heads) while small amount can be seen in the nuclei (red
arrow heads).
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In agreement with the literature, there was no evidence of cytotoxicity observed in our
data during the first 48 hours as shown in Fig.7.6.

Figure 7.6: Cytoxicity results for dextran-FITC coated SPIO nanoparticles on MIA PaCa2 cells
at three different concentrations. Note that cells were washed at 48 hours to remove unbound
nanoparticles and were incubated for another 3 days.
7.5: SDS-Page
In order to study the time dependent binding of the specific proteins the experiments were
carried out as following. Cells were lysed using 2% Triton, centrifuged for 1 minute at 1000rpm.
The supernatant was removed and the pellet containing nanoparticles bound proteins was washed
using PBS pH 7.4. The nanoparticle-associated proteins were resuspended in Laemmli [15]
reducing sample preparation buffer, boiled for 2 min, and used for SDS-PAGE. SDS
Polyacrylamide Gel Electrophoresis (SDS-PAGE) was run in order to separate nanoparticles
bound proteins based upon their size. The gels were then stained using Coomassie Blue
overnight, de-stained for 3-4 hours and imaged.
Assessment of the protein profile associated with the nanoparticles from SDS-PAGE, at
different times following incubation with cells, demonstrates a time-dependent distribution and
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association of the nanoparticles with different cellular compartments as reflected from their
different protein profiles (Fig. 7.7).

Figure 7.7: Coomassie stained SDS page gel image of protein bands associated with
Fe3O4 nanoparticles at different time points.
The SDS-PAGE demonstrates differences in some of the protein bands which change
with time, and are shown as A, B, C. The bands A and B are seen in 24 and 48 hours but not
before or after thatwhereas the band C appears only at 48 hours, suggesting association of the
nanoparticles with different subcellular compartments at different times following exposure to
cells.
7.6: Mass Spectroscopy data
Mass spectrometry was performedto identify the proteins associated with thebands
observed from SDS page gel. One of the gel bands (Band B in Figure 7.7) which showed
different optical densities at different time points during 0-72 hour time interval was selected.
The corresponding band of the control and the experimental samples at each time point was cut
and prepared for mass spectroscopy measurements. The proteins associated with these gel bands
were identified and the proteins present at different time points are listed in Table 1.
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Table 7.1: List of proteins that are bound to the nanoparticles at different time points as
identified by mass spectrometry. The sub cellular organelles associated with each protein are
listed in the right column revealing the possible location/distribution of the nanoparticles after
been exposed into the cells.

72 hours

48 hours

24 hours

Protein

Sub cellular organelle

Flotillin-2

Cell membrane, Endosome

Actin-like protein 6A

Nucleus

Septin-7

Cytoplasm

DnaJ homolog subfamily A member 1

Membrane, Nucleus, Cytoplasm

Nucleoporin Nup43

Nucleus, Chromosome

Glutamate receptor ionotropic, delta-2

Cell membrane

Heterogeneous nuclear
ribonucleoprotein H
RuvB-like 2

Nucleus › nucleoplasm

Eukaryotic translation initiation factor 2
subunit 3
Pigment epithelium-derived factor

Cytoplasm

Wnt inhibitory factor 1

Secreted

Cytochrome b-c1 complex subunit 1,
mitochondrial
Ubiquitin-60S ribosomal protein L40

Mitochondrion inner membrane

Actin, aortic smooth muscle

Cytoplasm › cytoskeleton

Cathepsin D

Lysosome

Protein DEK

Nucleus

Polymerase delta-interacting protein 3

Nucleus. Nucleus speckle. Cytoplasm

Nucleus, cytoplasm, membrane

Melanosome, Secreted

Cytoplasm, Nucleus

24 & 48 hours

Cell growth-regulating nucleolar protein Nucleus
Protein MAK16 homolog

Nucleus › nucleolus

Ribosome production factor 1

Nucleus › nucleolus

DDB1- and CUL4-associated factor 13

Nucleus › nucleolus

WD40 repeat-containing protein SMU1

Nucleus. Cytoplasm

Core histone macro-H2A.1

Nucleus. Chromosome

26S protease regulatory subunit 7

cytoplasm, Nucleus
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Data reveals the possible entrance of nanoparticles through endocytosis and targeted to
the cell nuclei within 48 hours. At 72 hours Cathepsin D , which is present in the lysosome, was
identified which suggests that the clearance of the nanoparticles through the lysosome does not
occurs immediately after the entrance, instead

proves the prolong accumulation of the

nanoparticles in the cells.
Also we determined the distribution of nanoparticles within cells at different time points
from the protein data and shown in Figure 7.8. From that also it can be observed that
nanoparticles are present in the nucleus within 24 hours and the clearing occurs only after 48
hours, since the relative percentage of proteins associated with nanoparticles has decreased at 72
hours.

Figure 7.8: Schematic representation of distribution of Fe3O4 nanoparticles within cells
at different time points estimated from the mass spectroscopy data.
7.7: Conclusions
In summary, the current study we have successfully functionalized nanoparticles for use in
investigating their binding and distribution in Mia PaCa-2 human pancreatic cancer cells. We
have investigated the traffic, distribution, and cytotoxicity, associated with these Fe3O4
nanoparticles, and demonstrated that there is a time-dependent distribution of these nanoparticles
into different cellular compartments. Furthermore, immunocytochemistry using co-localization
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of the nanoparticles with specific subcellular immune-markers is being carried out to further
confirm results from mass spectrometry. Results from these studies promise optimized drug
delivery and treatment of various diseases including cancers.
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CHAPTER 8 SUPERPARAMAGNETIC IRON OXIDE
NANOPARTICLES POTENTIATE CELLULAR ENTRY AND
RELEASE OF CANCER DRUG
8.1: Introduction
The various properties of nanoparticles (NPs) have been extensively explored for they
offer a broad spectrum of usage ranging from applications in electronic materials to medical
therapy [202]. In the last decade, gold [203,204], silver [205,206] and magnetic nanoparticles
[207] especially iron oxide emerged as potential candidates for the diagnosis and treatment of
various forms of cancer. The interaction of these NPs with cancer cells is widely studied for
careful understanding of several drug delivery and therapeutic approaches [208-210]. The Fe3O4
NPs [211] with their very unique superparamagnetic behavior play a prominent role in
modernizing the field of nanomedicine [190,212-214]. Several modifications including surface
functionalization of these Fe3O4NPswith anti-cancer drugs especially doxorubicin (Dox) have
been conducted over the last few years to investigate their efficacy when it comes to cancer
eradication [215]. Previous studies have reported that PEG (Polyethylene Glycol) functionalized
porous silica shell onto doxorubicin-conjugated Fe3O4 nanoparticle cores [216], PAMAM
(Poly(amidoamine)) coated Fe3O4 nanoparticles-doxorubicin complex [217], doxorubicin loaded
Fe3O4 nanoparticles modified with PLGA-PEG copolymers [218] could potentially be very
promising in therapeutic cancer treatment. Pancreatic cancer, a very devastating form of cancer,
is one of the major causes of death in the United States [219]. Dox conjugated NPs have been
extensively used for efficient drug delivery especially in human breast cancer cells. The anticancer drug Dox and the targeting ligand conjugated to the surface of a polymeric nanoparticle
works effectively for drug delivery in the human breast cancer cells. However, interaction of
nanoparticles with the human pancreatic cancer cell lines is not much explored. So a detailed
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investigation to understand the interactions and the intracellular distribution of these
nanoparticles into the human pancreatic cancer cells is very crucial.
In this chapter, we primarily present our work on the novel conjugation of Dox with a
labeling dye (FITC) onto dextran coated Fe3O4 nanoparticles using existing EDC/NHS technique
and their incorporation into the human pancreatic cancer cell line (MIA PaCa-2) for specific drug
targeting. This unique drug-dye dual conjugation of Fe3O4 NPs after penetration through the cell
membrane following phagocytosis [220], show a steady release of Dox into the nucleus of the
malignant cells. Our studies demonstrate that association of Dox onto the surface of
nanoparticles enhances its penetration into the cancer cells as compared to the unconjugated
drug.
8.2: Experimental details
8.2.1: Synthesis and characterization
The superparamagnetic Fe3O4 nanoparticles were synthesized coated with dextran and
cross linked following the exact procedure as described in Chapter 7.
8.2.2: Double labeling of dextran coated Fe3O4 nanoparticles with doxorubicin and FITC
(Dex- Fe3O4-DOX/FITC)
The pH of the dispersion (10 ml) of crosslinked SPIO NPs having a concentration of
4mg/ml was adjusted to 11 using the NaOH base (0.1 M) under continuous stirring for 1 h at
room temperature while purging with N2 gas. 100mg of monochloroacetic acid (MCA) was then
slowly added to the solution and the mixture was heated at 60˚C in a water bath and under N2
atmosphere. The reaction mixture was then dialyzed against deionized water to obtain the CMDSPIO. The DOX and FITC were attached to the CMD-SPIO NPs through EDC/NHS chemistry.
10 mg of EDC and 6 mg of NHS was added to 2.5 ml CMD-SPIO NPs suspension and stirred for
15 minutes at room temperature to activate the carboxyl groups. 1µmol of DOX was added to
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this mixture and subjected to stirring for 10 minutes, followed by the addition of 1 ml Ethylene
diamine hydrochloride (EDA). The resulting mixture was then dialyzed for 24 h to get rid of
unbound drug and EDA. 1µmol of FITC solution was added to this amino functionalized CMDSPIO NPs solution. After 2 h the mixture was subjected to short time interval frequent dialysis.
The final concentration of the SPIO NPs in the resulting DOX/FITC conjugated CMD-SPIO NPs
(Dex-SPIO-DOX/FITC) was estimated to be 2 mg/ml. All these experiments were carried out in
the dark.
8.2.3 Estimation of drug/dye encapsulation efficiencies
The fluorescence (FL) intensity of the fluorescent dyes was estimated using a Hitachi F2000 Fluorescence spectrophotometer. The calibration plots of fluorescence intensity versus the
concentration of the drug/dye were initially obtained as follows. The different concentrations (1,
5, 10, 25, 50 µg/ml) of DOX and FITC solutions were prepared from a stock solution of 500
µg/ml. A drop (equivalent to 10 µl) of DOX and FITC solutions was then added on a glass slide
at a time and the fluorescence images were taken at an optimized exposure time with the red
channel and the green channel respectively under the 40X oil immersed objective lenses (n=4).
For each concentration, the intensity plot profile was determined and the area under the curve
was calculated which is a measure of the intensity. Using these intensities, the calibration curves
were plotted as shown in the Figure S1. Adopting similar experimental procedure, the
fluorescence intensities (red and green) of the conjugated nanoparticle samples were also
determined.
8.2.4: Cellular studies
The intracellular distribution of surface functionalized NPs into the human pancreatic
carcinoma cell lines was imaged with an optical microscope (Axiovert 200, Zeiss). Equivalent
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amounts of MIA PaCa-2 cells were seeded in 35 mm poly L-lysine coated petri dishes with 2 ml
of cell growth medium containing Dulbecco’s modified essential medium (DMEM), 10% fetal
bovine serum (FBS) and 5% penicillin. The cells were then incubated for 24 h at 37°C in a
humidified 5% CO2 atmosphere. Following 24 h of incubation, half the medium was extracted
out and replaced with fresh medium containing 200 µg of Dex-SPIO-DOX/FITC. After 15
minutes of further incubation, the cells were washed three times with 1ml of PBS to remove any
excess and unbound NPs. Then, cells were fixed with 4% glutaraldehyde in PBS at 25°C for 30
mins. The same procedure was followed with the cells incubated with free DOX and FITC. The
concentrations of free DOX and FITC were kept approximately identical to that of the respective
drug and dye, present in Dex-SPIO-DOX/FITC. The experiments were carried out in triplicates.
8.3: Results and Discussions
The structural and magnetic characterizations of the nanoparticles are shown in Chapter
7. The as-synthesized NPs were coated with dextran (Dex-Fe3O4) and subsequently crosslinked
using epichlorohydrin (ECH). The crosslinked Fe3O4NPs were grafted with carboxylic groups
using monochlroacetic (MCA) acid to obtain the carboxymethylated Fe3O4NPs (CMD- Fe3O4).
The Dox and FITC were attached to the CMD- Fe3O4 NPs through EDC/NHS chemistry. EDC
and NHS were added to CMD- Fe3O4 NPs suspension to activate the carboxyl groups. Dox was
added to that mixture followed by the addition of Ethylene diamine hydrochloride (EDA) to react
with the activated carboxyl groups which provide amine group (-NH2) for further conjugation
with FITC. The detailed procedure is explained in section 3.2.5 and schematic representation of
the conjugation steps is shown in Fig. 8.1.
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Figure 8.1: Schematic representation of the synthesis of the magnetic drug delivery system
composed of Dextran coated Fe3O4 cores and DOX, FITC conjugations on the surface.
The hydrodynamic diameters of the Dex-SPIO and Dex-SPIO-DOX/FITC samples in
water at 25°C and pH of 7.4 were found to be 100±25 nm and 143±40 nm respectively, whereas
the respective zeta potential values are -17±3 mV and -9±1 mV. The changes in the size and the
surface charge upon functionalizing the NPs with DOX/FITC further confirm the conjugation of
the dye to the Dex-SPIO complex, besides the observation of the association of fluorescence.
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Using these intensities, the calibration curves were plotted as shown in the Figure 8.2.
Then following the same experimental procedure, the fluorescence intensities (red and green) of
the conjugated sample were determined to be 10% and 1% for FITC and Dox respectively.

Figure 8.2: Calibration fits of (a) FITC and (b) doxorubicin to estimate the drug/dye
quantification incorporated with Fe3O4 nanoparticles conjugate.
The calibration plots of fluorescence intensity versus the concentration of the free
drug/dye are shown in Fig 8.2. From the plots, using the fluorescence intensities (red and green)
of the conjugated sample the dye/drug loading efficiencies were determined to be 10% and 1%
for FITC and Dox respectively. To examine the efficacy of DOX on human pancreatic
carcinoma, experiments were conducted on the MIA PaCa 2 cells both in presence
(experimental) and absence (control) of the drug. Images of the control and experimental at 6 h
time point demonstrating the entry of the drug into the nucleus of the malignant cells are shown
in Figure 4(a).

99

Figure 8.3: (a) The fluorescence microscopy images of MIA PaCa 2 cells incubated with DOX.
Note cellular entry (especially into the nucleus) of the drug in the 6 h time point and cell
rounding. The inset shows blebbing of the cells prior to cell death. (b) The fluorescence
microscopy images of MIA PaCa 2 cells incubated with free DOX + free FITC (control) and
DOX-FITC conjugated Fe3O4 NPs at 15 mins. Green and red fluorescence represent FITC and
DOX respectively. Arrow heads indicates the DOX entry into the nucleus.
The images further demonstrate cell rounding and cell blebbing prior to their death,
clearly indicating the role of DOX in apoptosis. To examine the cellular internalization of
synthesized drug-dye-nano carrier conjugation, we conducted a series of fluorescence imaging
experiments on MIA PaCa-2 cells, grown attached to the tissue culture plates. The inherent
fluorescence of DOX (red) and FITC (green) were used to track their internalization. For
comparative studies, control experiments were carried out using the unconjugated DOX and
FITC. Figure 4(b) shows images collected at 15 minutes for control and experimental samples.
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The cells exposed to unconjugated DOX/FITC and Dex-SPIO-DOX/FITC show high
fluorescence intensities on the membrane indicating their strong binding. However, higher
fluorescence intensities (both green and red) are observed within the cells that were exposed to
the Dex-SPIO-DOX/FITC, as compared to the cells exposed to the unconjugated DOX/FITC.
These results indicate a rapid entry of Dex-SPIO-DOX/FITC into the cell than free DOX/FITC
which might be due to different entrance pathways. It has been well established that the free
DOX is taken up by the cells only through Fickian diffusion [221,222] while the cellular uptake
of Dex-SPIO-DOX/FITC is carried out most likely through endocytosis [223,224]. In this
context, conjugation of the drug with NPs facilitated cellular uptake of DOX through
endocytosis. For an efficient drug delivery system, not only the rapid uptake by the cancer cell is
crucial but also the drug release within the cell is of great importance. From Figure 4(b), it is
clearly observed that the distribution of DOX is very different upon NPs conjugation. In the
control experiments, the fluorescence intensities on the cell membrane are much higher than in
the cytoplasm implying that the unconjugated DOX as well as FITC are residing on the cell
membrane. On the other hand, the distribution of red fluorescence within the cells exposed to
conjugated DOX is different. The red and green fluorescence are partially separated and the red
fluorescence seems to accumulate within the nucleus while green fluorescence stays outside of it
indicating the release of DOX from the conjugation after entering the cells.
8.7: Conclusions
In summary, we were able to design and develop a drug delivery platform based on
Fe3O4NPs as the vehicle for an anti-cancer drug (Dox), attached to a model dye (FITC) for their
precise tracking. Employing the fluorescence microscopy, we were able to demonstrate that even
in the absence of any targeting ligand, the internalization of the Dox-FITC-Fe3O4is much higher
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as compared to the unconjugated Dox, enabling an efficient utilization of the anti-cancer drug.
In addition to rapid uptake of these NPs by live cells, our results also suggest that upon entering
the cells, Dox is cleaved from the conjugation, which might be due to the enzymatic reactions
that occur within the cells, and tends to accumulate in the nuclei fulfilling the major requirement
for an effective therapeutic system. We hypothesize that incorporation of targeting ligands into
this system could further enhance its performance and accordingly remodel it to be used in
different cell types.
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CHAPTER 9 CONCLUSIONS AND FUTURE WORK
Magnetic nanoparticles (MNPs), especially superparamagnetic Fe3O4 nanoparticles, have
attracted a great deal of attention due to their potential multimodal functionality in biomedical
applications. The research presented in this thesis is focused on exploiting the functionality of
Fe3O4 nanoparticles for two important biomedical applications; magnetic hyperthermia and drug
delivery.
The first part of this thesis focuses on understanding and optimizing the properties of
Fe3O4 nanoparticles for the maximum efficiency of heat generation. It is well known that the
SAR, which measures the magnetic hyperthermia efficiency, depends on magnetic properties of
the particles such as saturation magnetization, magnetic anisotropy, particle size distribution,
magnetic dipolar interactions, and the rheological properties of the target medium. We
synthesized Fe3O4 nanoparticles by two different methods, co-precipitation (CP) and the
hydrothermal (HT) synthesis, exhibiting similar structural and magnetic properties. Despite
having similar particle size (~ 12 nm) and saturation magnetization (~ 70 emu/g) they show
drastically different heating rates (SAR) at room temperature ~ 110 W/g (CP sample) and ~ 40
W/g (HT sample). This observed reduction in SAR has been explained by taking into account the
dipolar interactions using the so called T* model. Our analysis reveals that HT ferrofluid shows a
higher effective dipolar interaction and a wider distribution of magnetic core size of MNPs
compared to that of CP ferrofluid leading to a decrease in SAR.
Through this study we have been able to determine the effect of particle size,
polydispersity, magnetic anisotropy and dipolar interactions on the temperature dependent SAR,
qualitatively and quantitatively, which allow us to design nanoparticles for optimized SAR. For
example, nanoparticles of 14-15 nm size with a narrow size distribution and lower dipolar
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interactions would show SAR more than 200 W/g. Furthermore our results show that although
the HT method of synthesis leads to clustering of nanoparticles with strong dipolar interaction, it
is very versatile method in tailoring the particle size and distribution and hence further research
is necessary to figure out a suitable capping agent to avoid clustering of particles during the
synthesis.
We have also investigated the effect of the Gd-doping on the magnetic properties of
nanoparticles and the associated magnetic hyperthermia response of the ferrofluids. The
possibility of using Gd doped Fe3O4 nanoparticles as a dual modal T1-T2 contrast agent is being
currently explored by others. However, the possibility of using this doped system for magnetic
hyperthermia is not explored well. Both Gd-doped and un-doped iron oxide nanoparticles were

synthesized using co-precipitation method and coated with dextran. Our analysis on structural
and magnetic characterization data reveals that Gd (2.5 wt. %)-doping of Fe3O4 nanoparticles
leads to an increase in particle size and a reduced saturation magnetization. MHT experiments
revels that Gd-doped Fe3O4 exhibits a similar SAR value as that of un-doped Fe3O4 ferrofluid.
Our magnetic hyperthermia research demonstrates that this material is a potential candidate for
theronostics for multimodal contrast imaging and cancer treatment by hyperthermia.

From the analysis of temperature dependent SAR curves of Gd-doped Fe3O4 ferrofluids,
we found that the magnetocrystalline anisotropy (K) was found to decrease by 50% upon Gddoping. Among the very little literature on SAR of Gd-doped Fe3O4 nanoparticles present, a
recent study done by Douglas et. al [225] reports a SAR of 3.7±0.6 W/g Fe-1 at H0 = 3 kA/m and f
=111 kHz for 2% Gd doping. The authors attribute this observed enhancement in SAR to an
increase in magnetic anisotropy of Fe3O4 nanoparticles upon Gd doping, in contradiction to our
observation of a decrease in K dut to Gd doping. Further research is necessary to resolve this
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contradiction and further optimize the amount of Gd-doping to enhance SAR for cancer
treatment, as well as for a dual modal T1-T2 contrast agent.
We have made a comparative study of two different biocompatible coatings, dextran and
CA, on the colloidal and magnetic properties of Fe3O4nanoparticles as well as their impact on
magnetic hyperthermia efficiency was studied. Both the ferrofluids show similar magnetic and
hyperthermia properties, indicating that these surface modifications have no effect on their
performance. However, our concentration dependent magnetic hyperthermia results indicate that
the dilution of the sample should be done with extensive care as it may promote cluster
formation which in turn reduces the SAR value.
Moreover, upon exposure to cell growth medium that mimics the physiological
environment, formation of corona was observed for both dextran and CA coated nanoparticles as
seen from the hydrodynamic size measurements. It was observed that in CA coated particles
where, this protein corona forms faster, in several minutes to hours, causes aggregations in
solution and reduces SAR by ~ 45%. Dextran coated nanoparticles show a better stability at least
within first 3-6 hours upon exposure to the proteins in the cell growth medium exhibiting
excellent performance in both water and simulated physiological conditions. Furthermore, the
cytotoxicity studies done on human pancreatic cancer cells indicate that both dextran and CA
coated Fe3O4 ferrofluids are nontoxic to the cells at or below 100 µg/mL concentration. Though
further in vivo study is necessary in the future, these results imply that the dextran coated Fe3O4
dispersion could maintain their high heating capacity in physiological environments while CA
coating require further surface modification to reduce the non-specific protein adsorption.
However, the rapid formation of protein corona accelerates the endocytosis pathway leading to
the rapid entry of the nanoparticles into the cells which is a crucial factor for applications such as
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drug delivery and magnetic hyperthermia for cancer treatment [226-228]. Therefore it would be
necessary to perform in-vitro hyperthermia for these different coatings to investigate the effect of
the protein corona, which depends on the surface properties of the nanoparticles, on the
hyperthermia efficiency.
We also have successfully functionalized dextran coated Fe3O4 nanoparticles with
fluorescence dye, FITC, to investigate their binding and distribution in Mia PaCa-2 human
pancreatic cancer cells. Our results done on investigating the traffic, distribution, and
cytotoxicity, associated with these Fe3O4 nanoparticles, demonstrate that there is a timedependent distribution of these nanoparticles into different cellular compartments. It will be
interesting to explore the possibility of incorporating the magnetic hyperthermia with these
nanoparticles, for an enhanced cellular uptake as the magnetic heating may influence the
dynamics of nanoparticles through the cell membrane.
Furthermore, we were able to design and develop a drug delivery platform based on
Fe3O4 NPs as the vehicle for an anti-cancer drug (Dox), attached to a model dye (FITC) for their
precise tracking. Employing the fluorescence microscopy, we were able to demonstrate that even
in the absence of any targeting ligand, the internalization of the Dox-FITC-Fe3O4is much higher
as compared to the unconjugated Dox, enabling an efficient utilization of the anti-cancer drug.
In addition to rapid uptake of these NPs by live cells, our results also suggest that upon entering
the cells, Dox is cleaved from the conjugation, which might be due to the enzymatic reactions
that occur within the cells, and tends to accumulate in the nuclei fulfilling the major requirement
for an effective therapeutic system. We hypothesize that incorporation of targeting ligands into
this system could further enhance its performance and accordingly remodel it to be used in
different cell types.
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ABSTRACT
Fe3O4 NANOPARTICLES FOR MAGNETIC HYPERTHERMIA AND DRUG
DELIVERY; SYNTHESIS, CHARACTERIZATION AND CELLULAR STUDIES
by
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In recent years, magnetic nanoparticles (MNPs), especially superparamagnetic
Fe3O4nanoparticles, have attracted a great deal of attention because of their potential applications
in biomedicine. Among the other applications, Magnetic hyperthermia (MHT), where localized
heating is generated by means of relaxation processes in MNPs when subjected to a radio
frequency magnetic field, has a great potential as a non-invasive cancer therapy treatment.
Specific absorption rate (SAR), which measures the efficiency of heat generation, depends on
magnetic properties of the particles such as saturation magnetization (Ms), magnetic anisotropy
(K), particle size distribution, magnetic dipolar interactions, and the rheological properties of the
target medium.We have investigated MHT in two Fe3O4 ferrofluids prepared by co-precipitation
(CP) and hydrothermal (HT) synthesis methods showing similar physical particle size
distribution and Ms, but very different SAR ~ 110 W/g and ~ 40 W/g at room temperature. This
observed reduction in SAR has been explained by taking the dipolar interactions into account
using the so called T* model. Our analysis reveals that HT ferrofluid shows an order of
magnitude higher effective dipolar interaction and a wider distribution of magnetic core size of
MNPs compared to that of CP ferrofluid.
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We have studied dextran coated Gd-doped Fe3O4 nanoparticles as a potential candidate in
theronostics for multimodal contrast imaging and cancer treatment by hyperthermia. The effect
of surfactant on the MHT efficiency and cytotoxicity on human pancreatic cancer cells was
explored as well. Though further in vivo study is necessary in the future, these results imply that
the dextran coated Fe3O4 dispersion could maintain their high heating capacity in physiological
environments while citric acid coating require further surface modification to reduce the nonspecific protein adsorption. We have also investigated the traffic, distribution, and cytotoxicity,
associated with dextran functionalized FITC conjugated Fe3O4 nanoparticles, and our results
demonstrate that there is a time-dependent distribution of these nanoparticles into different
cellular compartments. Moreover, a novel conjugation of anti-cancer drug, Doxorubicin (Dox)
with a labeling dye (FITC) onto dextran coated Fe3O4 nanoparticles was developed using
existing EDC/NHS technique for specific drug targeting. The experiments on this unique drugdye dual conjugation with human pancreatic cancer cell line (MIA PaCa-2) show that association
of Dox onto the surface of nanoparticles enhances its penetration into the cancer cells as
compared to the unconjugated drug while releasing Dox into the nucleus of the malignant cells.
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